Donor strand complementation FIMH
Patent Information
- Application Number
- JP2023533648
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-17
- Filing Date
- 2021-11-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for immunologically effective and feasible ExPEC antigens that can be manufactured on a large scale for the treatment and prevention of urinary tract infections (UTIs), particularly targeting Uropathogenic Escherichia coli (UPEC) by inhibiting bacterial adhesion to urothelial cells.
Development of modified FimH polypeptides and nucleic acids that stabilize FimH in a low-affinity conformation by incorporating a donor strand complementary amino acid sequence, which can be expressed without FimC, to inhibit bacterial adhesion.
The modified FimH polypeptides effectively inhibit bacterial adhesion to urothelial cells, offering improved immunogenicity and stability, making them suitable for large-scale manufacturing and potential therapeutic applications.
Abstract
Description
[Technical Field]
[0001] Sequence List This application includes an electronically submitted sequence listing in ASCII text file format (VB67013 FF Seq List_ST25.txt; size: 356.838 bytes; and creation date: October 27, 2021), which is incorporated herein by reference in its entirety.
[0002] Technical field of inventions The present invention aims to provide novel modified FimH polypeptides, nucleic acids encoding them, and the use of polypeptides and nucleic acids in the treatment and / or prevention of diseases, particularly urinary tract infections (UTIs). [Background technology]
[0003] Uropathogenic Escherichia coli (UPEC) accounts for approximately 85% of all urinary tract infections (UTIs) (AR Ronald, Urinary tract infection in adults: Research priorities and strategies. Int. J. Antimicrob. Agents 17, 343-348; 2001). FimH, a type 1 pili apical localized adhesin, enables UPEC to colonize the bladder epithelium during UTIs by binding to mannosylated receptors on the urothelial surface (MA Mulvey, Induction and evasion of host defences by type 1-piliated uropathogenic Escherichia coli. Science 282, 1494-1497; 1998).
[0004] FimH is a phase variable, meaning that environmental signals influence its expression, allowing bacteria to adhere and avoid removal through urination (Infect. Immun. 1998, 66, 3303). Anti-FimH IgG is known to inhibit bacterial adhesion to the bladder in mice and monkeys, and this protective effect is associated with the presence of anti-FimH IgG in the urine (Langermann S, et al. Science. 1997 Apr 25;276(5312):607-11; Langermann S, et al. J Infect Dis. 2000 Feb;181(2):774-8). The exudation of serum functional IgG into the urogenital tract appears to be responsible for inhibiting bacterial adhesion.
[0005] The FimH protein has an N-terminal lectin domain (FimH) that binds to mannose via a pocket formed by three loops. L ), a 5-amino acid linker and a C-terminal pyrin domain (FimH) that attaches FimH to the pili. P It consists of ).
[0006] The crystal structure of FimH at different stages of fimbriae assembly is FimH P However, it was shown that it is composed of incomplete immunoglobulin (Ig)-like folding, which is stabilized through donor chain complementation interactions with chaperone FimC in the periplasm and with FimG at the time of pili assembly. P It adopts a single conformation, but FimH LIt is possible to assume at least two conformational states with different affinities for mannose: a relaxed (R) state, which is a high-affinity conformation, and a tense (T) state, which is a low-affinity conformation (D. Choudhury, X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science 285, 1061-1066 (1999); C.-S. Hung, Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol. Microbiol. 44, 903-915 (2002); I. Le Trong, Structural basis for mechanical force regulation of the adhesin FimH via finger trap-like β sheet twisting. Cell 141, 645-655 (2010); G. Phan, Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature 474, 49-53 (2011); S. Geibel, Structural and energetic basis of folded-protein transport by the FimD usher. Nature 496, 243-246 (2013)).
[0007] When FimH binds to FimC, FimH L and FimH P do not interact with each other, and FimH L adopts an extended conformation in which it is in the high-affinity mannose-binding state. When FimH binds to FimG, FimH L and FimH P interact closely, and FimHL It adopts a compact conformation in a low-affinity mannose-binding state. FimH P FimH L Through interaction with the base of FimH L It can allosterically reduce the ability of mannose to bind; mannose can be FimH L By joining, FimH P FimH does not interact with L Conformation is induced.
[0008] Previously, FimH in low affinity conformation L It has been reported that monoclonal antibodies against FimH elicits better inhibition of adhesion to the bladder compared to monoclonal antibodies against the post-mannose-bound morph (Tchesnokova et al., 2011, 'Type 1 Fimbrial Adhesin FimH Elicits an Immune Response That Enhances Cell Adhesion of Escherichia coli' Infect. Immun. 79(10): 3895-3904).
[0009] FimH with its uncompleted pyrin domain is unstable and prone to aggregation. Notably, FimH has typically been used as an antigen in a complex with the periplasmic protein FimC. While the FimC component did not directly contribute to reducing bacterial colonization in mice, it did contribute to stabilizing FimH, which protected FimH from degradation (Science 1997, 276, 607; FEMS Microbiol. Lett. 2000, 188, 147). To produce a stable FimH protein, FimG donor chain peptides (FimG residues 1-14) were added in vitro, and the fimbriae assembly chaperone FimC was detached from FimH (Sauer MM, et al. Nat Commun. 2016 Mar 7;7:10738.). LThe low-affinity conformation was also obtained by inserting a disulfide bridge that blocks the mannose pocket (Kisiela DI, et al. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19089-94).
[0010] The use of the FimHC complex involves a significant manufacturing burden, i.e., the production of two polypeptides that must then be complexed together presents undesirable complex and significant storage problems because the stability of the complex must be maintained during storage for the antigen to be effective. FimH with disulfide bridges L immunogenicity is variable due to the low molecular weight of this portion, and full-length FimH with disulfide bridges in the FimH L domain has proven difficult to express.
Prior Art Documents
Non-Patent Documents
[0011]
Non-Patent Document 1
Non-Patent Document 2
Non-Patent Document 3
Non-Patent Document 4
[0012] Therefore, there remains a significant need for ExPEC antigens that are immunologically effective and feasible for large-scale production. [Means for solving the problem]
[0013] Importantly, FimC stabilizes FimH in its elongated post-binding morphology (Nat. Commun. 2016, 7, 10738). Surprisingly, we have found that structural guide design makes it possible to stabilize the pre-binding morphology of FimH in the absence of FimC and / or improve the ability of the generated anti-FimH antibody to inhibit bacterial adhesion to urethral epithelial cells.
[0014] Therefore, a first aspect of the present invention is (a) FimH; or variants, fragments and / or fusions of FimH, and (b) Donor chain complementary amino acid sequence The present invention provides a polypeptide having an amino acid sequence containing or consisting of the following, wherein (b) is downstream of (a).
[0015] "Downstream" means, or includes, the amino acid sequence within the primary amino acid sequence of a polypeptide that is closer to the C-terminus of each polypeptide relative to the reference sequence.
[0016] Alternatively or additionally, the polypeptide of the present invention comprises or consists of the amino acid sequence X-(a)-L-(b)-Y, where "(a)" is the FimH polypeptide; or a variant, fragment, and / or fusion of FimH; "L" is an optional first linker; "(b)" is a donor chain complementary amino acid sequence; "X" is an optional N-terminal amino acid sequence; and "Y" is an optional C-terminal amino acid sequence, where "Y" is not derived from FimC or FimH or a fragment thereof.
[0017] A "donor chain complementary amino acid sequence" means an amino acid sequence capable of maintaining FimH in either a (a) relaxed (R) state, which is a high-affinity conformation, or (b) a stressed (T) state, which is a low-affinity conformation. In one preferred embodiment, the donor chain complementary amino acid sequence is capable of maintaining FimH in a low-affinity conformation, i.e., a stressed (T) state.
[0018] "Relaxed (R) state in high affinity conformation" means a mannose-binding affinity closer to that of FimH in the high affinity conformation (especially when complexed with FimH from which the polypeptide of the present invention is derived or primarily derived, particularly FimC) than in the low affinity conformation, for example, at least 51%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the mannose-binding affinity of FimH in the high affinity conformation, as disclosed in Kisiela DI, et al. Proc Natl Acad Sci US A. 2013 Nov 19;110(47):19089-94 d This means having or including <1.2 μM.
[0019] "A low-affinity conformation (T) state" means a mannose-binding affinity closer to that of FimH in the low-affinity conformation (especially when complexed with FimH from which the polypeptide of the present invention is derived or primarily derived, particularly FimC) than in the high-affinity conformation, for example, less than 50%, 40%, 30%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1% of the mannose-binding affinity of FimH in the high-affinity conformation, for example, as disclosed in Kisiela DI, et al. Proc Natl Acad Sci US A. 2013 Nov 19;110(47):19089-94. d This means or includes having approximately 300 μM or more (i.e., not having detectable mannose binding affinity). In one embodiment, the polypeptide of the present invention is in a low affinity conformation, for example, about 100 μM, 200 μM, 300 μM, 400 μM, 500 μM, 600 μM, 700 μM, 800 μM, 900 μM, or 1 mM K d It either has mannose binding affinity or does not have detectable mannose binding affinity.
[0020] The mannose-binding affinity can be determined using any suitable means known in the art, for example, by surface plasmon resonance (SPR) to confirm the binding affinity, binding specificity, and binding constant of the FimH construct to mannosylated bovine serum albumin (Man-BSA) and glucosylated bovine serum albumin (Glc-BSA) (negative control). See, for example, Rabani et al., 2018, 'Conformational switch of the bacterial adhesin FimH in the absence of the regulatory domain: Engineering a minimalistic allosteric system' J. Biol. Chem., 293(5):1835-1849, and Bouckaert J, et al. Mol Microbiol. 2005 Jan;55(2):441-55, which are incorporated herein by reference.
[0021] The conformation of FimH can also be evaluated by any preferred means known in the art, for example, by measuring the binding affinity of a conformation antibody using surface plasmon resonance, as described in the examples. Exemplary antibodies are capable of recognizing epitopes that overlap differently with the mannose-binding pocket of FimH, for example, antibodies that bind to epitopes that overlap with the mannose-binding pocket, for example, antibodies that bind to epitopes limited to only one loop of the mannose-binding pocket. Exemplary antibodies are disclosed in International Publication No. 2016 / 183501, or Kisiela DI, et al. Proc Natl Acad Sci US A. 2013 Nov 19;110(47):19089-94, Kisiela DI, et al. PLoS Pathog. 2015 May 14;11(5):e1004857, which are incorporated herein by reference. In one embodiment, the conformation antibody has a variable heavy chain (VH) sequence of SEQ ID NO: 125 and a variable light chain (VL) sequence of SEQ ID NO: 126. In another embodiment, the conformation antibody has a variable heavy chain (VH) sequence of SEQ ID NO: 127 and a variable light chain (VL) sequence of SEQ ID NO: 128.
[0022] TIFF2023553854000001.tif61170
[0023] As used herein, the term “amino acid” includes, as used herein, amino acids encoded by the standard 20 genes, as well as their corresponding stereoisomers in “D” form (compared to the natural “L” form), ω-amino acids and other naturally occurring amino acids, non-conventional amino acids (e.g., α,α-disubstituted amino acids, N-alkyl amino acids, etc.) and chemically derivatized amino acids (see below).
[0024] In other words, when an amino acid is specifically listed, such as "alanine," "Ala," or "A," this term means both L-alanine and D-alanine unless otherwise specified. Other non-conventional amino acids may also be suitable components for the polypeptide of the present invention, as long as the desired functional properties are retained by the polypeptide. With respect to the peptides shown, each encoded amino acid residue is represented, where appropriate, by a single-letter name corresponding to the conventional name of the conventional amino acid.
[0025] "Isolated" means that the features of the present invention (e.g., polypeptides) are provided in a context different from those that may be found in nature. Those skilled in the art will understand that "isolated" means that they have been "modified by human means" from their natural state, i.e., if found in nature, they have been altered or isolated from their original environment, or both. For example, a polynucleotide or polypeptide that is naturally present in a living organism is not "isolated" in such a living organism, but the same polynucleotide or polypeptide that has been separated from its naturally occurring coexisting material is "isolated" as the term is used in this disclosure. Furthermore, a polynucleotide or polypeptide that has been introduced into an organism by transformation, genetic engineering or any other recombination method will be understood as "isolated" even if it is still present in that organism, which may be living or non-living, unless such transformation, genetic engineering or other recombination method produces an organism that is otherwise indistinguishable from a naturally occurring organism.
[0026] "Polypeptide" means or includes polypeptides and proteins.
[0027] A "variant" of a polypeptide includes insertions, deletions, and / or substitutions that are either conserved or non-conserved. In particular, a mutant polypeptide may be a variant that does not exist in nature (i.e., not present in nature or not known to exist in nature). A variant may have at least 50% sequence identity with a reference sequence, e.g., at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5%.
[0028] Sequence identity or identity can be determined by the Smith-Waterman homology search algorithm as implemented in the MPSRCH program (Oxford Molecular), using an affine gap search with parameter gap-opening penalty = 12 and gap-extensioning penalty = 1, or by the Needleman-Wunsch comprehensive alignment algorithm (see, for example, Rubin (2000) Pediatric. Clin. North Am. 47:269-285), using default parameters (e.g., using the EBLOSUM62 scoring matrix, with gap-opening penalty = 10.0 and gap-extensioning penalty = 0.5). This algorithm is conveniently implemented in the needle tool in the EMBOSS package. Unless otherwise specified, when this application refers to sequence identity to a specific reference sequence, identity is intended to be calculated over the entire length of that reference sequence. Alternatively, percent identity can be determined using the LALIGN program (Huang and Miller, Adv. Appl. Math. (1991) 12:337-357, the disclosure of which is incorporated herein by reference) on the ExPASy site website www.ch.embnet.org / software / LALIGN_form.html, for example, using the comprehensive alignment option, the scoring matrix BLOSUM62, the opening gap penalty-14, and the extension gap penalty-4. Alternatively, percent sequence identity between two polypeptides can be determined using a suitable computer program, such as AlignX, Vector NTI Advance 10 (from Invitrogen), or the GAP program (from the University of Wisconsin Genetic Computing Group).
[0029] It will be understood that percentage identity is calculated with respect to the polymer (e.g., polypeptide or polynucleotide) whose sequence is aligned.
[0030] Fragments and variants can be prepared using protein manipulation and site-directed mutagenesis methods well known in the art (see, for example, Molecular Cloning: a Laboratory Manual, 3rd edition, Sambrook & Russell, 2001, Cold Spring Harbor Laboratory Press, the disclosure thereof is incorporated herein by reference).
[0031] Those skilled in the art will understand that the polypeptide of the present invention, or its fragments, variants, or fusions, may contain one or more modified or derivatized amino acids.
[0032] Chemical derivatives of one or more amino acids can be achieved by reaction with functional side groups. Examples of such derivatized molecules include those in which a free amino group is derivatized to form amine hydrochlorides, p-toluenesulfonyl groups, carboxybenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups, or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and ethyl esters, or other types of esters and hydrazides. Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. Peptides containing naturally occurring amino acid derivatives of 20 standard amino acids are also included in chemical derivatives. For example, 4-hydroxyproline can substitute proline; 5-hydroxylysine can substitute lysine; 3-methylhistidine can substitute histidine; homoserine can substitute serine; and ornithine can substitute lysine. Derivatives also include peptides containing one or more additions or deletions, as long as the desired activity is maintained. Other possible modifications include amidation, amino-terminal acylation (e.g., acetylation or thioglycolate amidation), terminal carboxylamilation (e.g., using ammonia or methylamine), and similar terminal modifications.
[0033] Those skilled in the art will further understand that peptidomimetics compounds can also be useful. That is, “polypeptides” include peptidomimetics compounds that exhibit endolysin activity. The term “peptidomimetics” means compounds that mimic the conformation and desirable characteristics of a particular polypeptide as a therapeutic agent.
[0034] For example, polypeptides described herein include not only molecules in which amino acid residues are linked by peptide (-CO-NH-) bonds, but also molecules in which the peptide bonds are reversed. Such retro-inverso peptidomimetics can be prepared using methods known in the art, such as those described in Meziere et al. (1997) J. Immunol. 159, 3230-3237 (the disclosure of which is incorporated herein by reference). Such retro-inverse peptides containing NH-CO bonds instead of CO-NH peptide bonds are far more resistant to proteolysis. Alternatively, the polypeptides of the present invention may be peptidomimetics compounds in which one or more amino acid residues are linked by -γ(CH2NH)- bonds instead of conventional amide bonds.
[0035] It will be understood that polypeptides can be conveniently blocked at their N-terminus or C-terminus, for example, by amidation, in order to help reduce their susceptibility to exoproteolytic digestion.
[0036] As discussed herein, the polypeptides of the present invention can be modified using a variety of non-coding or modified amino acids, such as D-amino acids and N-methylamino acids. In addition, putative bioactive conformations can be stabilized by covalent modifications such as cyclization, or by the incorporation of lactams, disulfides, or other types of crosslinks. Methods for the synthesis of cyclic homodetic and cyclic heterodetic peptides, including disulfide, sulfide, and alkylene crosslinks, are disclosed in U.S. Patent No. 5,643,872. Other examples of cyclization methods are discussed and disclosed in U.S. Patent No. 6,008,058, the relevant disclosures in this document are incorporated herein by reference. A further approach to the synthesis of cyclically stabilized peptidomimetics compounds is ring-closing metathesis (RCM).
[0037] A polypeptide "fusion" includes a polypeptide that is fused to any other polypeptide. For example, a polypeptide may contain one or more additional amino acids that are inserted internally and / or at the N and / or C terminus into the amino acid sequence of the polypeptide of the present invention.
[0038] In other words, as used herein, in one embodiment, the polypeptide of the first aspect of the present invention includes a polypeptide to which an enzyme domain from a different source (e.g., from a source different from the polypeptide of the first aspect of the present invention) is fused. Examples of suitable enzyme domains include L-alanoyl-D-glutamate endopeptidase; D-glutamyl-m-DAP endopeptidase; peptide cross-linking specific endopeptidase; N-acetyl-β-D-glucosaminidase (=muramoyl hydrolase); N-acetyl-β-D-muramidase (=lysozyme); and soluble transglycosylase. N-acetylmuramoyl-L-alanine amidase from other sources may also be used (see Loessner, 2005, Current Opinion in Microbiology 8: 480-487, for which its disclosure is incorporated herein by reference).
[0039] For example, the polypeptide can be fused to a polypeptide such as glutathione-S-transferase (GST) or protein A to facilitate the purification of the polypeptide. Examples of such GST fusions are well known to those skilled in the art. Similarly, the polypeptide can be fused to an oligohistidine tag such as His6, or to an antibody-recognized epitope such as a well-known Myc-tag epitope. Fusions to any fragment, variant, or derivative of the polypeptide are also included within the scope of the present invention. It will be understood that fusions (or their variants or derivatives) that retain desirable properties, such as antigenic activity, are preferred. It is also particularly preferred if the fusion is suitable for use in the manner described herein.
[0040] For example, the fusion may include further parts that confer desirable characteristics to the polypeptide of the present invention; for example, a part may be useful for the detection or isolation of the polypeptide, for promoting the uptake of the polypeptide into cells, or for directing the secretion of the protein from cells. A part may be, for example, a biotin moiety, a radioactive moiety, a fluorescent moiety, such as a small molecule fluorophore or a green fluorescent protein (GFP) fluorophore, as is well known to those skilled in the art. A part may be an immunogenic tag, such as a Myc tag, as is well known to those skilled in the art, or a lipophilic molecule or polypeptide domain capable of promoting the uptake of the polypeptide into cells, as is well known to those skilled in the art.
[0041] Those skilled in the art will understand that the polypeptides of the present invention also include pharmaceutically acceptable acid or base addition salts of the polypeptides described herein. Acids used to prepare pharmaceutically acceptable acid addition salts of the above-mentioned base compounds useful in the present invention are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, superphosphate, acetate, lactate, citrate, acid citrate, tartrate, hydrogen tartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoic acid [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoic acid)] salt.
[0042] Pharmaceutically acceptable base addition salts can also be used to produce pharmaceutically acceptable salt forms of polypeptides. Chemical bases that can be used as reagents to prepare pharmaceutically acceptable base salts of the compounds of the present invention, which are originally acidic, are those that form non-toxic base salts using such compounds. Such non-toxic base salts include, but are not limited to, those derived from such pharmaceutically acceptable cations, such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), water-soluble amine addition salts such as ammonium or N-methylglucamine-(meglumine), and other base salts of lower alkanolammonium and pharmaceutically acceptable organic amines.
[0043] Polypeptides, or their fragments, variants, fusions, or derivatives, may also be lyophilized for storage and re-prepared in a suitable carrier before use. Any suitable lyophilization method (e.g., spray drying, cake drying) and / or re-preparation technique may be utilized. It will be understood by those skilled in the art that lyophilization and re-preparation may result in varying degrees of loss of activity, and that the level of use may need to be adjusted upward to offset this. Preferably, lyophilized (freeze-dried) polypeptides lose about 20% or less, or about 25% or less, or about 30% or less, or about 35% or less, or about 40% or less, or about 45% or less, or about 50% or less of their activity (before lyophilization) upon rehydration.
[0044] The polypeptides of the present invention are preferably provided in a purified or substantially purified form, that is, substantially free from other polypeptides, particularly other E. coli or host cell polypeptides (e.g., free from naturally occurring polypeptides), and generally at least about 50% pure (by weight), for example, at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.5%, or 100% pure by weight (i.e., less than 50% of the composition consists of other expressed polypeptides). In other words, the antigen in the composition is isolated from the whole organism in which the antigen molecule is expressed.
[0045] (a) FimH may be from any Escherichia coli or Klebsiella pneumoniae bacterial species (or a variant, fragment and / or fusion thereof), but alternatively or additionally, (a) may be: (A) The amino acid sequences of SEQ ID NO: 1 (Genbank registration number ELL41155.1 (FimH of E. coli J96)), SEQ ID NO: 2, SEQ ID NO: 100 (Genbank registration number ABG72591.1 (FimH of UPEC 536)), SEQ ID NO: 101, SEQ ID NO: 102 (Genbank registration number AAN83822.1 (FimH of CFT073)), SEQ ID NO: 103, SEQ ID NO: 104 (Genbank registration number AJE58925.1 (FimH of E. coli 789)), SEQ ID NO: 105, SEQ ID NO: 106 (Genbank registration number AAC35864.1, corresponding to nucleic acid sequence AF089840.1 (FimH of IHE3034)), or SEQ ID NO: 107, (B) Amino acid sequences containing 1 to 10 single amino acid changes, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 single amino acid changes, compared to Sequence ID No. 1 (Genbank registration number ELL41155.1 (FimH of E. coli J96)), Sequence ID No. 2, Sequence ID No. 100 (Genbank registration number ABG72591.1 (FimH of UPEC 536)), Sequence ID No. 101, Sequence ID No. 102 (Genbank registration number AAN83822.1 (FimH of CFT073)), Sequence ID No. 103, Sequence ID No. 104 (Genbank registration number AJE58925.1 (FimH of E. coli 789)), Sequence ID No. 105, Sequence ID No. 106 (Genbank registration number AAC35864.1, corresponding to nucleic acid sequence AF089840.1 (FimH of IHE3034)), or Sequence ID No. 107, (C) Sequence ID 1 (Genbank registration number ELL41155.1 (FimH of E. coli J96)), Sequence ID 2, Sequence ID 100 (Genbank registration number ABG72591.1 (UPEC) Amino acid sequences having at least 70% sequence identity with sequence number 536 (FimH), SEQ ID NO: 101, SEQ ID NO: 102 (Genbank registration number AAN83822.1 (FimH of CFT073)), SEQ ID NO: 103, SEQ ID NO: 104 (Genbank registration number AJE58925.1 (FimH of E. coli 789)), SEQ ID NO: 105, SEQ ID NO: 106 (Genbank registration number AAC35864.1, corresponding to nucleic acid sequence AF089840.1 (FimH of IHE3034)), or SEQ ID NO: 107, for example, amino acid sequences having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, and / or (D) Sequence ID 1 (Genbank registration number ELL41155.1 (FimH of E. coli J96)), Sequence ID 2, Sequence ID 100 (Genbank registration number ABG72591.1 (UPEC) At least 10 consecutive amino acids from sequence number 536 (FimH), SEQ ID NO: 101, SEQ ID NO: 102 (Genbank registration number AAN83822.1 (FimH of CFT073)), SEQ ID NO: 103, SEQ ID NO: 104 (Genbank registration number AJE58925.1 (FimH of E. coli 789)), SEQ ID NO: 105, SEQ ID NO: 106 (Genbank registration number AAC35864.1, corresponding to nucleic acid sequence AF089840.1 (FimH of IHE3034)), or SEQ ID NO: 107, for example, at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 275, 280, 290 or 300 consecutive amino acid fragments It includes or consists of.
[0046] TIFF2023553854000002.tif33170[Sequence ID 1] - GenBank:ELL41155.1 (Underlined part is a signal peptide)
[0047] TIFF2023553854000003.tif21170[SEQ ID NO: 2] - GenBank:ELL41155.1-21aa signal peptide
[0048] TIFF2023553854000004.tif26170[SEQ ID NO: 100] - Genbank registration number ABG72591.1 (FimH of UPEC 536) (Underlined part is signal peptide)
[0049] TIFF2023553854000005.tif22170[SEQ ID NO: 101] - Genbank registration number ABG72591.1 (FimH in UPEC 536) Negative signal peptide
[0050] TIFF2023553854000006.tif17170TIFF2023553854000007.tif11170[Sequence ID 102] - Genbank registration number AAN83822.1 (FimH of CFT073) (Underlined part is signal peptide)
[0051] TIFF2023553854000008.tif20170[SEQ ID NO: 103] - Genbank registration number AAN83822.1 (FimH of CFT073) negative signal peptide
[0052] TIFF2023553854000009.tif26170 [Sequence ID 104] Genbank registration number AJE58925.1 (FimH of E. coli 789) (Underlined part is signal peptide)
[0053] TIFF2023553854000010.tif22170 [Sequence ID 105] Genbank registration number AJE58925.1 (FimH of E. coli 789) negative signal peptide
[0054] TIFF2023553854000011.tif26170 [Sequence ID 106] Genbank registration number AAC35864.1, (FimH of IHE3034), (Underlined part is signal peptide)
[0055] TIFF2023553854000012.tif21170[SEQ ID NO: 107] Genbank registration number AAC35864.1, (FimH of IHE3034), negative signal peptide
[0056] Alternatively or additionally, the polypeptides are fragments, variants, fusions, and / or derivatives capable of inducing a specific immune response to polypeptides selected from the group consisting of SEQ ID NO: 1 (Genbank registration number ELL41155.1 (FimH of E. coli J96)), SEQ ID NO: 2, SEQ ID NO: 100 (Genbank registration number ABG72591.1 (FimH of UPEC 536)), SEQ ID NO: 101, SEQ ID NO: 102 (Genbank registration number AAN83822.1 (FimH of CFT073)), SEQ ID NO: 103, SEQ ID NO: 104 (Genbank registration number AJE58925.1 (FimH of E. coli 789)), SEQ ID NO: 105, or SEQ ID NO: 106 (Genbank registration number AAC35864.1, corresponding to nucleic acid sequence AF089840.1 (FimH of IHE3034)), SEQ ID NO: 107.
[0057] "Specific immune response" means or includes the ability to induce an immune response within the subject body that produces (e.g., stimulates the release of) an antibody capable of binding to a specific amino acid sequence. Preferably, the antibody is capable of binding in vivo, i.e., under physiological conditions in which the amino acid sequence or polypeptide is present on or inside the subject's body. Such binding specificity can be determined by methods well known in the art, such as ELISA, immunohistochemistry, immunoprecipitation, Western blotting, and flow cytometry using transfected cells expressing the polypeptide of the present invention.
[0058] Alternatively or additionally, the immune response may be an immune activation response, such as a protective immune response. Polypeptides may be capable of in vitro protective immune responses and / or in vivo protective immune responses when administered to a subject.
[0059] In the presence of co-stimulatory signals, T cells differentiate into specific phenotypic subtypes. Several of these subtypes are involved in the suppression or termination of innate inflammatory signals. "Immune-activating response" means and / or includes polypeptides that induce or are capable of inducing an immune response in a subject, which does not result in the suppression or termination of inflammation or inflammatory signals, and preferably results in the activation or enhancement of inflammation or inflammatory signals (e.g., cytokines).
[0060] In vivo protective immune responses can occur in mammals. Alternatively or additionally, mammals include armadillos (dasypus novemcinctus), baboons (papio anubis; papio cynocephalus), camels (camelus bactrianus, camelus dromedarius, camelus ferus), cats (felis catus), dogs (canis lupus familiaris), horses (equus ferus caballus), ferrets (mustela putorius furo), goats (capra aegagrus hircus), guinea pigs (cavia porcellus), golden hamsters (mesocricetus auratus), kangaroos (macropus rufus), llamas (lama glama), mice (mus musculus), pigs (sus scrofa domesticus), rabbits (oryctolagus cuniculus), rats (rattus norvegicus), and rhesus monkeys (macaca). The group is selected from the following: mulatta, sheep (ovis aries), non-human primates, and humans (Homo sapiens).
[0061] Alternatively or additionally, FimH L To reduce flexibility and mannose binding, FimH L FimH pTwo glycine residues in the linker that connects to the nucleotide can be deleted. For example, glycine residues 196 and 197 of polypeptide moiety (a) compared to SEQ ID NO: 1, glycine residues 180 and 181 of polypeptide moiety (a) compared to SEQ ID NO: 1, glycine residues 183 and 184 of polypeptide moiety (a) compared to SEQ ID NO: 100, glycine residues 183 and 184 of polypeptide moiety (a) compared to SEQ ID NO: 102, and glycine residues 183 and 184 of polypeptide moiety (a) compared to SEQ ID NO: 104: (i) whether it exists; or (ii) It is omitted.
[0062] Alternatively or additionally, one or more amino acids in a polypeptide known or predicted to be N-glycosylated or O-glycosylated are substituted with amino acids that are not glycosylated or are poorly glycosylated, such as serine (S), aspartic acid (D), alanine (A), or glutamine (Q). Alternatively or additionally, only the polypeptide moiety (a) contains amino acid substitutions to reduce or eliminate N- and / or O-glycosylation.
[0063] N- and / or O-glycosylation can be determined using any suitable means known in the art, for example, using NetNGlyc 1.0 and NetOGlyc 4.0 servers using default settings (accessible at http: / / www.cbs.dtu.dk / services / NetOGlyc / and http: / / www.cbs.dtu.dk / services / NetOGlyc / ).
[0064] Alternatively or additionally, the polypeptide moiety (a) may include one or more of the following amino acid substitutions compared to SEQ ID NO: 2: N28S, N91D, N249D, N256D, or the positions of SEQ ID NOs: 101, 103, and 105, e.g., one, two, three, or four of the amino acid substitutions corresponding to these positions in SEQ ID NO: 2.
[0065] Alternatively or additionally, the donor chain complementary amino acid sequence (b) is: (i) 6 to 28 amino acids of SEQ ID NO: 3; or fragments thereof and / or variants, (ii) 8 to 36 amino acids of SEQ ID NO: 4; or fragments thereof and / or variants. It includes or consists of.
[0066] ASATIQA ADVTITVNGKVVAK PCTVSTT [SEQ ID NO: 3] - FimG donor strand and adjacent region (underlined portion is the donor strand) PSMDKSKLT ENTLQLAIISRIKLYYRP AKLALPPDQ [SEQ ID NO: 4] - FimC donor strand and adjacent region (underlined portion is the donor strand)
[0067] Alternatively or additionally, part (b) may contain or consist of 6 to 28 amino acids (or fragments and / or variants thereof) of SEQ ID NO: 3, where these amino acids are: (i) Amino acids 1-28 of SEQ ID NO: 3; or fragments and / or variants thereof, (ii) Amino acids 2-27 of SEQ ID NO: 3; or fragments and / or variants thereof, (iii) Amino acids 3-26 of SEQ ID NO: 3; or fragments and / or variants thereof, (iv) Amino acids 4-25 of SEQ ID NO: 3; or fragments and / or variants thereof, (v) Amino acids 5-24 of SEQ ID NO: 3; or fragments and / or variants thereof, (vi) Amino acids 6-23 of SEQ ID NO: 3; or fragments and / or variants thereof, (vii) Amino acids 7-22 of SEQ ID NO: 3; or fragments and / or variants thereof, (viii) Amino acids 8-21 of SEQ ID NO: 3; or fragments and / or variants thereof, (ix) Amino acids 9-20 of SEQ ID NO: 3; or fragments and / or variants thereof, (x) Amino acids 10-19 of SEQ ID NO: 3; or fragments and / or variants thereof, (xi) Amino acids 11-18 of SEQ ID NO: 3; or fragments and / or variants thereof, (xii) Amino acids 12-17 of SEQ ID NO: 3; or fragments thereof and / or variants. Selected from the group consisting of .
[0068] Alternatively or additionally, part (b) may contain or consist of 8 to 36 amino acids (or fragments and / or variants thereof) of SEQ ID NO: 4, where these amino acids are: (i) Amino acids 1-36 of SEQ ID NO: 4; or fragments and / or variants thereof, (ii) Amino acids 2-35 of SEQ ID NO: 4; or fragments and / or variants thereof, (iii) Amino acids 3-34 of SEQ ID NO: 4; or fragments and / or variants thereof, (iv) Amino acids 4-33 of SEQ ID NO: 4; or fragments and / or variants thereof, (v) Amino acids 5-32 of SEQ ID NO: 4; or fragments and / or variants thereof, (vi) Amino acids 6-31 of SEQ ID NO: 4; or fragments and / or variants thereof, (vii) Amino acids 7-30 of SEQ ID NO: 4; or fragments and / or variants thereof, (viii) Amino acids 8-29 of SEQ ID NO: 4; or fragments and / or variants thereof, (ix) Amino acids 9-28 of SEQ ID NO: 4; or fragments and / or variants thereof, (x) Amino acids 10-27 of SEQ ID NO: 4; or fragments and / or variants thereof, (xi) Amino acids 11-26 of SEQ ID NO: 4; or fragments and / or variants thereof, (xii) Amino acids 12-25 of SEQ ID NO: 4; or fragments and / or variants thereof, (xiii) Amino acids 13-24 of SEQ ID NO: 4; or fragments and / or variants thereof, (xiv) Amino acids 14-23 of SEQ ID NO: 4; or fragments and / or variants thereof, (xv) Amino acids 15-24 of SEQ ID NO: 4; or fragments and / or variants thereof, (xvi) Amino acids 16-23 of SEQ ID NO: 4; or fragments thereof and / or variants. Selected from the group consisting of .
[0069] Alternatively or additionally, the donor chain complementary amino acid sequence (b) is: (A) Amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6, (B) Amino acid sequences containing 1 to 10 single amino acid changes compared to SEQ ID NO: 5 or SEQ ID NO: 6, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 single amino acid changes, (C) At least seven consecutive amino acids from SEQ ID NO: 5, for example, a fragment of at least eight, nine, ten, eleven, twelve, or thirteen consecutive amino acids from SEQ ID NO: 5, and / or (D) At least seven consecutive amino acids from SEQ ID NO: 6, for example, fragments of at least eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, or eighteen consecutive amino acids from SEQ ID NO: 6 It includes or consists of.
[0070] ADVTITVNGKVVAK [SEQ ID NO: 5] - FimG donor chain ENTLQLAIISRIKLYYRP [SEQ ID NO: 6] - FimC donor strand
[0071] In one preferred embodiment, the donor chain complementary amino acid sequence (b) comprises or consists of SEQ ID NO: 5. Alternatively or additionally, the donor chain complementary amino acid sequence (b) comprises or consists of SEQ ID NO: 6.
[0072] Alternatively or additionally, the donor chain complementary amino acid sequence (b) is: (i) Directly ligated to the C-terminus of (a), or (ii) It is linked to the C-terminus of (a) via the first linker.
[0073] Alternatively or additionally, the first linker (or "L") contains or consists of 2 to 20 amino acids, e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. Alternatively or additionally, the first linker is proline-started. In a preferred embodiment, the first linker is proline-started. Alternatively or additionally, the first linker contains or consists of polar amino acids, for example, the first linker is composed entirely of polar amino acids, or if the first linker is proline-started, the remaining amino acids are polar. Alternatively or additionally, the first linker is: (i) PGDGN[SEQ ID NO: 7], or its variant or fusion, (ii) DNKQ[SEQ ID NO: 8], or its variant or fusion It includes or consists of.
[0074] In one preferred embodiment, the first linker (or "L") includes or consists of Sequence ID No. 7.
[0075] Alternatively or additionally, the polypeptide may contain, at its N-terminus, C-terminus, and / or internally, a protein purification affinity tag, e.g., 6, 7, 8, 9, or 10 consecutive histidines.
[0076] Alternatively or additionally, "X" contains a cell secretion leader sequence. Alternatively or additionally, the polypeptide is: (i) Upstream of (a), or (ii) N-terminus of the polypeptide It contains a cell secretion leader sequence.
[0077] Alternatively or additionally, the cell secretion leader sequence is: (i) METDTLLLWVLLLWVPGSTGD[SEQ ID NO: 9], or its variant or fusion, (ii) METDTLLLWVLLLWVPGSTGDAAQPARRARRTKLAL[SEQ ID NO: 10], or its variant or fusion, (iii) MRLLAKIICLMLWAICVA[SEQ ID NO: 11], or its variant or fusion, (iv) MGWSCIILFLVATATGVHS[SEQ ID NO: 12], or its variant or fusion, (v) METPAELLFLLLLWLPDTTG[SEQ ID NO: 13], or its variant or fusion, (vi) METDTLLLWVLLLWVPGSTG[SEQ ID NO: 108], or its variant or fusion, (vii) MEFGLSWVFLVAILEGVHC[SEQ ID NO: 14], or its variants or fusions Selected from the group consisting of .
[0078] Alternatively or additionally, "X" is a methionine (M) residue, particularly when the polypeptide is expressed in E. coli host cells.
[0079] Alternatively or additionally, the polypeptide may include a nanoparticle domain at its N-terminus or C-terminus. That is, in one embodiment, "X" includes a nanoparticle domain or "Y" includes a nanoparticle domain. "Nanoparticle domain" means or includes an amino acid sequence that is capable of self-assembling to form a protein complex, in particular a globular protein complex. "Self-assembly" means or includes assembly with other nanoparticle domains of the same type (for example, if a nanoparticle domain is a ferritin domain, it may assemble with other ferritin domains to form a protein complex such as a globular protein complex). In particular, the nanoparticle domains of the present invention are capable of self-assembly when they form part of the polypeptide of the present invention.
[0080] Alternatively or additionally, nanoparticle domains may include: (a) Ferritin (for example, [SEQ ID NO: 15] or [SEQ ID NO: 109] (Helicobacter pylori), [SEQ ID NO: 16] (Escherichia coli), or any one of [SEQ ID NO: 149] to [SEQ ID NO: 152] (stabilized E. coli)), or its variants and / or fragments, (b) iMX313 (e.g., [SEQ ID NO: 17]), or its variants and / or fragments, (c) mI3 (e.g., [SEQ ID NO: 18]), or its variants and / or fragments, (d) Encapsrin (e.g., [SEQ ID NO: 19]), or its variants and / or fragments, (e) Self-assembling viral coat proteins such as the Acinetobacter phage AP205 coat protein (NCBI reference sequence: NP_085472.1), hepatitis B virus core protein (HBc) [SEQ ID NO: 110], or bacteriophage Qβ [SEQ ID NO: 111], or their variants and / or fragments. Selected from the group consisting of .
[0081] TIFF2023553854000013.tif61170TIFF2023553854000014.tif147170
[0082] Alternatively or additionally, nanoparticle domains may include: (i) Directly linked to a polypeptide, or (ii) Linked to the polypeptide via a second linker.
[0083] Alternatively or additionally, the second linker may contain or consist of 2 to 20 amino acids, e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. Alternatively or additionally, the second linker may contain or consist of glycine (G) and / or serine (S), or contain at least 50% glycine (G) and / or serine (S), e.g., at least 60%, 70%, 80%, 90%, or 95% glycine (G) and / or serine (S).
[0084] Alternatively or additionally, a second linker could be: (a) GSSGSGSGS[SEQ ID NO: 112] or its variants or fusions, (b) GGSGS[SEQ ID NO: 113] or its variants or fusions, (c) GGS or its variants or fusions, (d) SGSHHHHHHHHGGS[SEQ ID NO: 114] or its variants or fusions, (e) AKFVAAWTLKAAA[SEQ ID NO: 115] or its variants or fusions, (f) GGGGSLVPRGSGGGGS[SEQ ID NO: 116] or its variants or fusions, (g) EAAAKEAAAKEAAAKA [SEQ ID NO: 117] or its variants or fusions, (h) SGSFVAAWTLKAAAGGS[SEQ ID NO: 118] or its variants or fusions, and (i) SGSGSGGGGGGS[SEQ ID NO: 119] or its variants or fusions Selected from the group consisting of .
[0085] Linker AKFVAAWTLKAAA [SEQ ID NO: 115], also known as the pan-HLA DR-binding epitope (PADRE), has been proposed as a suitable carrier epitope for use in the development of synthetic and recombinant vaccines, as disclosed in “Linear PADRE T Helper Epitope and Carbohydrate B Cell Epitope Conjugates Induce Specific High Titer IgG Antibody Responses” 10.4049 / jimmunol.164.3.1625, whose disclosure is incorporated herein by reference. + These are peptides that activate T cells. The linkers GGGGSLVPRGSGGGGS[SEQ ID NO: 116] and EAAAKEAAAKEAAAKA[SEQ ID NO: 117] are rigid linkers that cannot fold into an α-helix.
[0086] Alternatively or additionally, nanoparticle domains may include: (a) Upstream of (a), (b) N-terminus of the polypeptide, (c) Downstream of (b), or (d) C-terminus of polypeptide It is located there.
[0087] In a further embodiment, a designed de novo polypeptide monomer (and nucleic acid molecule encoding it) is provided that can self-assemble into nanoparticles (i.e., protein nanoparticles). Host cells, vectors or constructs, and methods for producing or using such polypeptide monomers and protein nanoparticles are also provided. The present invention further relates to nanoparticles (NPs) having a surface structure comprising or consisting of at least one such polypeptide monomer and optionally carrying one or more antigen molecules.
[0088] The polypeptide monomer of the present invention is mutated compared to its wild-type counterpart monomer (i.e., E. coli bacterial ferritin [SEQ ID NO: 16]), thereby possessing increased stability, such as improved thermal stability or folding stability in kcal / mol compared to its wild-type counterpart monomer, thereby enabling the formation of self-assembled nanoparticles having improved thermal stability or folding stability in kcal / mol compared to its wild-type counterpart nanoparticles.
[0089] "Increased stability" means that a molecule, when compared to a control molecule or its wild-type counterpart under equivalent or identical conditions (e.g., temperature and / or pH), has a lower rate of unfolding, reduced misfolding, reduced protein domain migration, reduced protein domain translocation, increased half-life (in vitro or in vivo), increased storage life, increased melting temperature (Tm) (meaning an increase in the melting temperature of at least one molecule if there are two or more molecules), a lower folding free energy value (kcal / mol), a lower binding free energy value (as in the case of subunits that bind to other subunits to form macromolecules), or a combination thereof. For clarity of example, if the stability of a molecule is increased through one or more mutations ("stabilizing mutations," such as one or more amino acid mutations), then "control molecule" or its "wild-type counterpart" means a molecule that does not contain one or more stabilizing mutations. With respect to the present invention, monomers or nanoparticles may be described as having increased stability (e.g., increased thermal stability and / or increased folding stability and / or increased binding stability) compared to their wild-type counterpart molecules under equivalent (or identical) conditions. As used herein, “conditions” includes experimental and physiological conditions. See, for example, U.S. Patent Application Publication 2011 / 0229507; Clapp et al., 2011 J. Pharm. Sci. 100(2): 388-401; and Rossi et al., 2016 Infect. Immun. 84(6): 1735-1742, which discuss increased stability via adjuvants and evaluate antigen stability under altered pH, hydration, and temperature conditions.For clarity, “stability” refers to a molecule’s resistance to unfolding at a particular temperature and is typically identified as “thermal stability” as commonly communicated in the art by the molecule’s melting temperature, specifically an increase in the molecule’s melting temperature (there may be two or more melting temperatures for oligomeric proteins such as dimers or trimers); see Kumar et al. 2000 Prot. Eng. Des. Sel. “Factors enhancing protein thermostability” 13(3): 179-191; and Miotto et al. 2018 bioRxiv doi: 10.1101 / 354266 “Insights on protein thermal stability: a graph representation of molecule interactions”. Where context requires, the thermal stability of two or more molecules (such as two or more modified molecules, each containing one or more stabilizing mutations) can be compared and one can be said to be more thermally stable than the other (i.e., having enhanced or increased thermal stability compared to the other). In this specification, stability, particularly thermal stability, can be provided by a delta stability (dStability or dS) scoring method, which is the computer-determined difference between the relative thermal stability of an in silico mutant protein and that of a control or its wild-type counterpart (i.e., an unstabilized mutant) protein. Methods for determining dStability are publicly known (International Publication No. 2020 / 079586 (PCT / IB2019 / 058777), MALITO et al.) and may include the use of tools such as Molecular Operating Environment (MOE) software (see: Molecular Operating Environment (MOE) software; available from Chemical Computing Group, WorldWideWeb (www).chemcomp.com). dS is measured in kcal / mol. Lower dS values indicate higher protein stability, and higher dS values indicate lower protein stability.It can be determined that the mutant polypeptide of the present invention has higher relative thermal stability (kcal / mol) compared to the non-mutant polypeptide under the same or equivalent experimental conditions. It can be further determined that the mutant polypeptide of the present invention has a lower dS value than the non-mutant polypeptide under the same or equivalent experimental conditions. It will be understood from the present invention that the mutant polypeptide having a lower dS value compared to the non-mutant polypeptide under the same or equivalent experimental conditions is more stable than the non-mutant polypeptide. The enhanced stability can be evaluated using differential scanning calorimetry (DSC) or differential scanning fluorescence (DSF) as discussed in Bruylants et al. 2005 Curr. Med. Chem. 12: 2011-2020 and Calorimetry Sciences' "Characterizing Protein stability by DSC" (Life Sciences Application Note, Doc. No. 20211021306, February 2006). The increase in (thermal) stability is assessed by DSC or DSF, as is the temperature transition midpoint (T). mThis can be characterized as an increase of at least about 2°C. See, for example, Thomas et al., 2013 Hum. Vaccin. Immunother. 9(4): 744-752. A “significant” increase, or enhancement, of thermal stability is defined as an increase of at least 5°C in the complex’s calculated Tm (e.g., calculated by the protocol provided in Example 4.7 of MALITO et al., International Publication No. 2020 / 079586 (PCT / IB2019 / 058777)). For clarity, as used herein, “stability” means the folding free energy of the molecule (reported in kilocalories per mole (kcal / mol)) and can be determined using various known techniques (see the Examples section herein and, for example, Zhang et al. 2012 Bioinformatics 28(5): 664-671), and can be specified as “folding stability.” Where the context requires, the folding stabilities of two or more molecules can be compared, and one can be said to be more stable than the other because it has a lower folding free energy value (kcal / mol). The monomer or nanoparticle of the present invention can be identified as having higher / enhanced folding stability compared to a control molecule or its wild-type counterpart under the same or equivalent conditions (e.g., experimental conditions). A “significant” increase, or enhancement, of folding stability is defined as a change in folding free energy (kcal / mol) that is at least 100 kcal / mol lower than the change in folding free energy (kcal / mol) of the comparison molecule under equivalent or identical conditions.
[0090] In one embodiment, the polypeptide monomer of the present invention comprises an amino acid sequence having at least 80% sequence identity with amino acid sequence SEQ ID NO: 16, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, and has one or more mutations selected from the group consisting of glycine (G) (T34G mutation) at a position aligned with residue 34 of SEQ ID NO: 16, aspartic acid (D) (N70D mutation) at a position aligned with residue 70 of SEQ ID NO: 16, isoleucine (I) (V72I mutation) at a position aligned with residue 72 of SEQ ID NO: 16, and alanine (A) (S124A mutation) at a position aligned with residue 124 of SEQ ID NO: 16.
[0091] In one preferred embodiment, the polypeptide monomer comprises an amino acid sequence having at least 80% sequence identity with respect to amino acid sequence SEQ ID NO: 16, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, and having glycine (G) (T34G mutation) at a position aligned with residue 34 of SEQ ID NO: 16, aspartic acid (D) (N70D mutation) at a position aligned with residue 70 of SEQ ID NO: 16, isoleucine (I) (V72I mutation) at a position aligned with residue 72 of SEQ ID NO: 16, and alanine (A) (S124A mutation) at a position aligned with residue 124 of SEQ ID NO: 16. In one embodiment, the polypeptide monomer contains an amino acid sequence having at least 80% sequence identity with amino acid sequence SEQ ID NO: 149, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In one embodiment, the polypeptide monomer contains the amino acid sequence of SEQ ID NO: 149.
[0092] In one embodiment, the polypeptide monomer comprises an amino acid sequence having at least 80% sequence identity with amino acid sequence SEQ ID NO: 16, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and having glycine (G) (T34G mutation) at a position aligned with residue 34 of SEQ ID NO: 16, isoleucine (I) (V72I mutation) at a position aligned with residue 72 of SEQ ID NO: 16, and alanine (A) (S124A mutation) at a position aligned with residue 124 of SEQ ID NO: 16. In one embodiment, the polypeptide monomer comprises an amino acid sequence having at least 80% sequence identity with amino acid sequence SEQ ID NO: 150, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In one embodiment, the polypeptide monomer contains the amino acid sequence of SEQ ID NO: 150.
[0093] In one embodiment, the polypeptide monomer contains an amino acid sequence having at least 80% sequence identity with amino acid sequence SEQ ID NO: 16, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, and has glycine (G) (T34G mutation) at a position aligned with residue 34 of SEQ ID NO: 16, and alanine (A) (S124A mutation) at a position aligned with residue 124 of SEQ ID NO: 16. In one embodiment, the polypeptide monomer contains an amino acid sequence having at least 80% sequence identity with amino acid sequence SEQ ID NO: 151, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In one embodiment, the polypeptide monomer contains the amino acid sequence of SEQ ID NO: 151.
[0094] In one embodiment, the polypeptide monomer contains an amino acid sequence having at least 80% sequence identity with amino acid sequence SEQ ID NO: 16, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and has glycine (G) (T34G mutation) at a position aligned with residue 34 of SEQ ID NO: 16. In one embodiment, the polypeptide monomer contains an amino acid sequence having at least 80% sequence identity with amino acid sequence SEQ ID NO: 152, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In one embodiment, the polypeptide monomer contains the amino acid sequence of SEQ ID NO: 152.
[0095] The designed de novo polypeptide monomers of the present invention can be self-assembled into generally spherical nanoparticles (for example, having an outer surface structure diameter of about 5 nm to about 30 nm, preferably about 15 to 20 nm). Therefore, the polypeptide monomers of the present invention can be used to provide self-assembled protein nanoparticles, which optionally carry (e.g., present) at least one antigen molecule, at least one immunostimulant molecule, or at least one antigen molecule and at least one immunostimulant molecule. In one embodiment, the nanoparticles of the present invention (e.g., generally spherical nanoparticles of the present invention) consist of 24 monomer subunits (for example, at least one monomer subunit being the polypeptide monomer of the present invention) and have a basic shape with octahedral symmetry.
[0096] Nanoparticles (naturally occurring and recombinant nanoparticles, e.g., computer-designed nanoparticles), methods for producing them, and their use, for example, as scaffolds (or "carriers") for one or more antigens or immunostimulants (i.e., "pharmaceutically acceptable nanoparticles") are known in the art.
[0097] As will be recognized by the Art (see, for example, Ueda et al. 2020 eLife 9: e57659; Pan et al. 2020 Adv. Mater. 32:2002940), the protein nanoparticles of the present invention can be used as a “scaffold” to support (conjugate to the outer surface structure of the nanoparticle, i.e., link, adhere, link, fuse, bind or ligate) an antigen, an immunostimulant, multiple copies of the same antigen, multiple copies of the same immunostimulant, a mixture of two or more antigens (e.g., two, three, four, or five antigens; i.e., divalent, trivalent, tetravalent, or pentavalent antigens), a mixture of two or more immunostimulants (e.g., two, three, four, or five immunostimulants; i.e., divalent, trivalent, tetravalent, or pentavalent immunostimulants), or a mixture of one or more antigens and one or more immunostimulants.
[0098] In certain embodiments, the self-assembly of polypeptide monomers places its N-terminus on the outer / outer surface of the nanoparticles and its C-terminus on the inner / core / inner surface of the nanoparticles. This presents the antigen or immunostimulant, which is linked to the N-terminus of the polypeptide monomer, on the outer surface of the assembled nanoparticles. In other embodiments, the self-assembly of polypeptide monomers places its C-terminus on the outer / outer surface of the nanoparticles and its N-terminus on the inner / core / inner surface of the nanoparticles. This presents the antigen or immunostimulant, which is linked to the C-terminus of the polypeptide monomer, on the outer surface of the assembled nanoparticles. In certain other embodiments, the antigen or immunostimulant is linked to the N-terminus of the polypeptide monomer, and the antigen or immunostimulant (the same or different antigen and / or immunostimulant) is linked to the C-terminus of the polypeptide monomer, thereby presenting the antigen or immunostimulant on the outer surface and supporting it on the inner surface of the assembled nanoparticles.
[0099] Accordingly, embodiments of the present invention provide nanoparticles supporting one or more molecules (for example, when the molecules are heterogeneous compared to one or more (e.g., all) of the nanoparticle monomers), wherein the one or more molecules are optionally presented on the outer surface of the nanoparticles. If the one or more presented molecules (e.g., antigens and / or immunostimulants) are proteins (e.g., all are proteins), they can be expressed as part of a polypeptide monomer (i.e., as a fusion protein monomer), thereby the self-assembly of the nanoparticles resulting in the presentation of the proteins on the outer surface of the nanoparticles. Alternatively, the protein-presenting molecules can be linked to the assembled nanoparticles by chemical or biological conjugate, for example, as discussed herein and as known in the art. In further embodiments of the present invention, the presented molecules are polysaccharides or oligosaccharides (such as bacterial capsular polysaccharides); the sugars can be linked to the nanoparticles to provide a "sugar conjugate". See Polonskaya et al. 2017 J. Clin. Invest. 127(4):1492-1504; Pan et al. 2020 Adv. Mater. 32:2002940.
[0100] In one embodiment, the antigen is a polypeptide having an amino acid sequence comprising (a) FimH; or variants, fragments and / or fusions of FimH, and (b) a donor chain complementary amino acid sequence, where (b) is downstream of (a) or as otherwise described herein. In one embodiment, the antigen comprises or comprises an amino acid sequence having at least 80% sequence identity to amino acid sequence SEQ ID NO: 124, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In one embodiment, the antigen comprises or comprises the amino acid sequence of SEQ ID NO: 124.
[0101] In one embodiment, a nanoparticle of an amino acid sequence having at least 80% sequence identity to amino acid sequence SEQ ID NO: 130 or 153, for example, at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In one embodiment, the nanoparticle contains or consists of the amino acid sequence of SEQ ID NO: 130 or 153.
[0102] Accordingly, certain embodiments of the present invention provide polypeptides (i.e., polypeptide monomers) that can be self-assembled into nanoparticles, as well as nucleic acid molecules encoding such polypeptides. The amino acid sequences herein may include, or further include, a tag (e.g., a purified tag such as histidine (e.g., a 6×His tag), an enterokinase tag, or a myc tag), and a linker between the polypeptide monomer and one or more molecules (e.g., an antigen) supported by the nanoparticles. Furthermore, the nucleic acid sequences herein may encode amino acid sequences including a tag and / or a linker.
[0103] Alternatively or additionally, the polypeptide contains a phenylalanine (Phe, F) residue at the N-terminus of the FimH polypeptide. Alternatively or additionally, if the polypeptide contains a nanoparticle domain at the C-terminus or N-terminus, the polypeptide contains a phenylalanine (Phe, F) or aspartic acid (Asp, D) residue at the N-terminus of the mature polypeptide, i.e., after cleavage or removal of the leader sequence, if present. The presence of an aspartic acid (Asp, D) residue at the N-terminus of a mature polypeptide containing a nanoparticle domain at the C-terminus or N-terminus is associated with improved secretion of the polypeptide when expressed by mammalian host cells.
[0104] Alternatively or additionally, polypeptides include: (a) Sequence ID No. 20, or its variants and / or fragments, (b) Sequence ID No. 21, or its variants and / or fragments, (c) Sequence ID No. 22, or its variants and / or fragments, (d) Sequence ID No. 23, or its variants and / or fragments, (e) Sequence ID No. 24, or its variants and / or fragments, (f) Sequence ID No. 25, or its variants and / or fragments, (g) Sequence ID No. 26, or its variants and / or fragments, (h) Sequence ID No. 27, or its variants and / or fragments, (i) Sequence ID No. 28, or its variants and / or fragments, (j) Sequence ID No. 29, or its variants and / or fragments, (k) Sequence ID No. 30, or its variants and / or fragments, (l) Sequence ID No. 31, or its variants and / or fragments, (m) Sequence ID No. 32, or its variants and / or fragments, (n) Sequence ID No. 33, or its variants and / or fragments, (o) Sequence ID No. 34, or its variants and / or fragments, (p) Sequence ID No. 35, or its variants and / or fragments, (q) Sequence ID No. 36, or its variants and / or fragments, (r) Sequence ID No. 37, or its variants and / or fragments, (s) Sequence ID No. 38, or its variants and / or fragments, (t) Sequence ID No. 39, or its variants and / or fragments, (u) Sequence ID No. 40, or its variants and / or fragments, (v) Sequence ID No. 41, or its variants and / or fragments, (w) Sequence ID No. 42, or its variants and / or fragments, (x) Sequence ID No. 43, or its variants and / or fragments, (y) Sequence ID No. 44, or its variants and / or fragments, (z) Sequence ID No. 79, or its variants and / or fragments, (aa) Sequence ID No. 80, or its variants and / or fragments, (bb) Sequence ID No. 81, or its variants and / or fragments, (cc) Sequence ID No. 82, or its variants and / or fragments, (dd) Sequence ID No. 83, or its variants and / or fragments, (ee) Sequence ID No. 84, or its variants and / or fragments, (ff) Sequence ID No. 85, or its variants and / or fragments, (gg) Sequence ID No. 86, or its variants and / or fragments, (hh) Sequence ID No. 87, or its variants and / or fragments, (ii) Sequence ID No. 88, or its variants and / or fragments, (jj) Sequence ID No. 89, or its variants and / or fragments, (kk) Any one of sequence numbers 120-124, 129-143, and 153, or a variant or / or fragment thereof. It contains or consists of the corresponding amino acid sequence.
[0105] In one preferred embodiment, the polypeptide comprises or consists of an amino acid sequence corresponding to SEQ ID NO: 123 or SEQ ID NO: 124. In one embodiment, the polypeptide comprises or consists of an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 123 or SEQ ID NO: 124, for example, at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 123 or SEQ ID NO: 124.
[0106] Alternatively or additionally, the mannose-binding affinity of polypeptides is at least 20% lower than that of natural FimH complexed with natural FimC (FimHC complex), for example, at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100% lower.
[0107] The mannose binding affinity can be determined by any suitable means known in the art, for example, surface plasmon resonance can be used to confirm the binding affinity, binding specificity, and binding constant of the FimH construct to Man-BSA and Glc-BSA (negative control), see, for example, Rabani et al., 2018, 'Conformational switch of the bacterial adhesin FimH in the absence of the regulatory domain: Engineering a minimalistic allosteric system' J. Biol. Chem., 293(5):1835-1849, which is incorporated herein by reference.
[0108] "Innate FimH" means or includes wild-type FimH, particularly wild-type FimH from which domain(a) of the polypeptide of the present invention is derived (optionally, with the innate N-terminal secretory sequence removed). Alternatively or additionally, it means or includes E. coli J96 FimH (e.g., SEQ ID NO: 1 or SEQ ID NO: 2), E. coli UPEC 536 FimH (e.g., SEQ ID NO: 100 or SEQ ID NO: 101), E. coli CFT073 FimH (e.g., SEQ ID NO: 102 or SEQ ID NO: 103), E. coli 789 FimH (e.g., SEQ ID NO: 104 or SEQ ID NO: 105), E. coli IHE3034 FimH (e.g., SEQ ID NO: 106 or SEQ ID NO: 107). In particular, it includes FimH in the relaxed (R) state (see above) which is a high-affinity conformation.
[0109] "Natural FimC" means or includes wild-type FimC (optionally, with the natural N-terminal secretory sequence removed). Alternatively or additionally, it means or includes E. coli J96 FimC, UPEC 536 FimC, E. coli CFT073 FimC, E. coli 789 FimC, and E. coli IHE3034 FimC.
[0110] "Innate FimC complexed with FimH" and "FimHC complex" refer to the forms and / or conditions taught in the Examples section of this specification, as described in: (a) D. Choudhury, X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science 285, 1061-1066 (1999), (b) C.-S. Hung, Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol. Microbiol. 44, 903-915 (2002), (c) I. Le Trong, Structural basis for mechanical force regulation of the adhesin FimH via finger trap-like β sheet twisting. Cell 141, 645-655 (2010), and (d) G. Phan, Crystal structure of the FimD usher bound to its Cognate FimC-FimH substrate. Nature 474, 49-53 (2011), or (e) S. Geibel, Structural and energetic basis of folded-protein transport by the FimD usher. Nature 496, 243-246 (2013), meaning or including FimH bound to FimC as found in the periplasm of bacteria naturally expressing FimH and FimC.
[0111] Alternatively or additionally, the anti-FimH immunogenicity of polypeptides is at least 20% higher than that of innate FimH complexed with innate FimC (in particular, including FimH in the relaxed (R) state (see above), which is a high-affinity conformation), and for example, at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, or 500% higher. Immunogenicity can be determined by any preferred means known in the art, e.g., ELISA or Luminex (see the Examples section).
[0112] Alternatively or additionally, polypeptide-induced self-aggregation is at least 20% lower than that of innate FimH, for example, at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100% lower.
[0113] "Polypto-induced autoaggregation is at least X% lower than that of innate FimH" (where "X" is a number between 20 and 100) means or includes that, when expressed by bacteria instead of innate FimH, the polypeptide induces at least X% less bacterial autoaggregation than otherwise equivalent bacteria expressing equivalent innate FimH. "Equivalent innate FimH" means or includes innate FimH for the bacteria used in the test, innate FimH from which the polypeptide of the present invention is derived, and / or innate FimH for which the polypeptide of the present invention has the highest sequence identity.Any suitable means known in the art for measuring autoaggregation may be used, but in one embodiment, the method used is as follows: Schembri, Christiansen and Klemm, 2001, 'FimH-mediated autoaggregation of Escherichia coli' Molecular Microbiology, 41(6), 1419-1430, incorporated herein by reference; or Thomas et al., 2002, 'Bacterial adhesion to target cells enhanced by shear force' Cell, 109(7):913-23, incorporated herein by reference; or Hartman et al., 2012, 'Inhibition of bacterial adhesion to live human cells: Activity and cytotoxicity of synthetic mannosides' FEBS Letters, 586(10): 1459-1465, incorporated herein by reference; or Falk et al., 1995, 'Chapter 9: Bacterial This refers to the method described in Adhesion and Colonization Assays' Meth. Cell, Biol., 45:165-192; or, as incorporated herein by reference, Zanaboni et al., 2016, 'A novel high-throughput assay to quantify the vaccine-induced inhibition of Bordetella pertussis adhesion to airway epithelia' BMC Microbiol., 16:a215.Alternatively or additionally, bacterial adhesion is measured (briefly) using the BAI assay as follows: UPEC strains genetically engineered to express the mCherry fluorescent marker are incubated for 30 minutes in a 96-well plate with a monolayer of SV-HUC-1 in the presence of specific serum or positive / negative controls against FimH derivatives. After adhesion, cells are thoroughly washed to remove unbound bacteria and fixed with formaldehyde. Finally, specific fluorescence signals associated with adhered bacteria are recorded using an automated high-content screening microscope (Opera Phenix) and quantified using Harmony software.
[0114] Alternatively or additionally, polypeptides can inhibit bacterial adhesion by at least 20%, for example, at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or up to 100%.
[0115] "Inhibits bacterial adhesion" means or includes adhesion that occurs instead via bacterial motility, or adhesion as measured by the bacterial adhesion assays described above (e.g., using the BAI assay) and / or in the Examples section of this specification.
[0116] Alternatively or additionally, polypeptides can inhibit guinea pig red blood cell agglutination by at least twofold, for example, at least threefold, fourfold, fivefold, tenfold, fifteenfold, twentyfold, twenty-fivefold, thirtyfold, fortyfold, fiftyfold, sixtyfold, seventyfold, eightyfold, ninetyfold, or even one hundredfold.
[0117] "Inhibits hemagglutination" means or includes inhibition of hemagglutination as measured by hemagglutination inhibition assays (HAIs) as described in Hultgren et al, Infect Immun 1986, 54, 613-620 and Jarvis C et al, ChemMedChem 2016, 11, 367-373 and / or the Examples section.
[0118] Alternatively or additionally, the polypeptide is soluble, meaning that at least 50% w / w of the polypeptide (e.g., present in a mixture and / or expressed by cells) is in a soluble form, and for example, at least 60%, 70%, 80%, 90%, 95%, or 100% of the polypeptide is in a soluble form.
[0119] A second aspect of the present invention provides nucleic acids, such as DNA or RNA, that encode a polypeptide according to the first aspect.
[0120] Alternatively or additionally, nucleic acids are codon-optimized for expression in selected prokaryotic or eukaryotic cells, e.g., yeast cells (e.g., Saccharomyces cerevisiae, Pichia pastoris), insect cells (e.g., Spodoptera frugiperda Sf21 or Sf9 cells), or mammalian cells (Expi293, Expi293GNTI (Life Technologies), Chinese hamster ovary (CHO) cells, and human fetal kidney 293 cells (HEK293)). “Codon-optimized” means modifications with respect to codon use frequency that can increase the translation efficiency and / or half-life of the nucleic acid. Codon usage frequency / optimization tables for numerous organisms are well known and publicly available (e.g., as provided by Athey et al. 2017 BMC Bioinf. 18:391). Codon optimization can be performed using any preferred means known in the art, for example, the method provided by GeneArt.
[0121] Alternatively or additionally, nucleic acids are: (1) Sequence ID No. 45, or its variants and / or fragments, (2) Sequence ID No. 46, or its variants and / or fragments, (3) Sequence ID No. 47, or its variants and / or fragments, (4) Sequence ID No. 48, or its variants and / or fragments, (5) Sequence ID No. 49, or its variants and / or fragments, (6) Sequence ID No. 50, or its variants and / or fragments, (7) Sequence ID No. 51, or its variants and / or fragments, (8) Sequence ID No. 52, or its variants and / or fragments, (9) Sequence ID No. 53, or its variants and / or fragments, (10) Sequence ID No. 54, or its variants and / or fragments, (11) Sequence ID No. 55, or its variants and / or fragments, (12) Sequence ID No. 56, or its variants and / or fragments, (13) Sequence ID No. 57, or its variants and / or fragments, (14) Sequence ID No. 58, or its variants and / or fragments, (15) Sequence ID No. 59, or its variants and / or fragments, (16) Sequence ID No. 60, or its variants and / or fragments, (17) Sequence ID No. 61, or its variants and / or fragments, (18) Sequence ID No. 62, or its variants and / or fragments, (19) Sequence ID No. 63, or its variants and / or fragments, (20) Sequence ID No. 64, or its variants and / or fragments, (21) Sequence ID No. 65, or its variants and / or fragments, (22) Sequence ID No. 66, or its variants and / or fragments, (23) Sequence ID No. 67, or its variants and / or fragments, (24) Sequence ID No. 68, or its variants and / or fragments, (25) Sequence ID No. 69, or its variants and / or fragments, (26) Sequence ID No. 70, or its variants and / or fragments, (27) Sequence ID No. 71, or its variants and / or fragments, (28) Sequence ID No. 72, or its variants and / or fragments, (29) Sequence ID No. 73, or its variants and / or fragments, (30) Sequence ID No. 74, or its variants and / or fragments, (31) Sequence ID No. 75, or its variants and / or fragments, (32) Sequence ID No. 76, or its variants and / or fragments, (33) Sequence ID No. 77, or its variants and / or fragments, (34) Sequence ID No. 90, or its variants and / or fragments, (35) Sequence ID No. 91, or its variants and / or fragments, (36) Sequence ID No. 92, or its variants and / or fragments, (37) Sequence ID No. 93, or its variants and / or fragments, (38) Sequence ID No. 94, or its variants and / or fragments, (39) Sequence ID No. 95, or its variants and / or fragments, (40) Sequence ID No. 96, or its variants and / or fragments, (41) Sequence ID No. 97, or its variants and / or fragments, (42) Sequence ID No. 98, or its variants and / or fragments, (43) Sequence ID 99, or its variants and / or fragments It contains or consists of a nucleic acid sequence corresponding to [the specified value].
[0122] Those skilled in the art will immediately understand that if the nucleic acid of the present invention is RNA, then T in the nucleic acid sequence of the present invention (e.g., SEQ ID NOs. 45-99) is replaced by U.
[0123] A third aspect of the present invention provides a vector comprising the nucleic acid of the second aspect. Alternatively or additionally, the vector is a plasmid, for example, an expression plasmid. Alternatively or additionally, the plasmid is selected from the group consisting of pCDNA3.1 (Life Technologies), pCDNA3.4 (Life Technologies), pFUSE, pBROAD, pSEC, pCMV, pDSG-IBA, and pHEK293 Ultra, etc. Alternatively or additionally, the plasmid is suitable for expression in bacterial host cells and is selected from the group consisting of pACYCDuet-1, pTrcHis2A, pET21, pET15TEV, pET22b+, pET303 / CT-HIS, PET303 / CT, pBAD / Myc-His A, pET303, pET24b(+), etc.
[0124] Alternatively or additionally, the vector may be a viral vector, such as an RNA viral vector. Alternatively or additionally, the viral vector may be selected from the group consisting of adenovirus vectors and CHAD.
[0125] A fourth aspect of the present invention provides a cell, such as a host cell, comprising the nucleic acid of the second aspect or the vector of the fourth aspect.
[0126] Suitable mammalian host cells are known in the art. Alternatively or additionally, the cells may lack N-acetylglucosaminyltransferase I (GnTI) activity. Alternatively or additionally, the cells may include Expi293, Expi293GNTI (Life Technologies), Chinese hamster ovary (CHO) cells, NIH-3T3 cells, 293-T cells, Vero cells, HeLa cells, PERC.6 cells (ECACC accession number 96022940), Hep G2 cells, MRC-5 (ATCC CCL-171), WI-38 (ATCC CCL-75), fetal rhesus monkey lung cells (ATCC CL-160), Madin-Darby bovine kidney ("MDBK") cells, Madin-Darby canine kidney ("MDCK") cells (e.g., MDCK(NBL2), ATCC CCL34; or MDCK 33016, DSM ACC) 2219) Selected from a group consisting of baby hamster kidney (BHK) cells, such as BHK21-F, HKCC cells, and human fetal kidney 293 cells (HEK293).
[0127] Suitable bacterial host cells are known in the art. Exemplary bacterial host cells include any of the following and their derivatives: Escherichia coli derived from strains BL21(DE3), HMS174(DE3), Origami2(DE3), BL21DE3T1r, or T7shuffle express.
[0128] A fifth aspect of the present invention provides a method for producing a polypeptide as defined in the first aspect by expressing a protein in cells as defined in the fourth aspect.
[0129] A sixth aspect of the present invention provides a vaccine comprising a polypeptide as defined in the first aspect, a nucleic acid as defined in the second aspect, and / or a vector as defined in the third aspect. Alternatively or additionally, the vaccine comprises an adjuvant.
[0130] In one embodiment, the vaccine of the present invention comprises a polypeptide as defined in the first embodiment and an adjuvant comprising any one of 3D-MPL, QS21, and liposomes, for example, liposomes containing cholesterol.
[0131] The inventors have surprisingly found that a vaccine containing an adjuvant comprising liposomes containing 3D-MPL, QS21, and cholesterol, for example, the AS01 adjuvant, can produce an improved immune response. “Improved immune response” means or includes an increased level of immunoglobulin G (IgG) in the serum and / or urine of an animal, such as a mouse immunized with the reference or vaccine, compared to the level of IgG in the serum and / or urine of the animal. “Increased level of IgG in serum and / or urine” means or includes at least a 2-fold increase in cells, for example, at least 3-fold, 4-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, or 50-fold. The reference or control vaccine does not contain an adjuvant comprising liposomes containing 3D-MPL, QS21, and cholesterol; for example, the reference or control vaccine contains the PHAD adjuvant.
[0132] The inventors have also found, surprisingly, that vaccines comprising polypeptides as defined in the first embodiment, as well as adjuvants comprising liposomes containing 3D-MPL, QS21, and cholesterol, such as the AS01 adjuvant, are capable of inducing a protective immune response after one or two doses.
[0133] Immunogenic compositions (e.g., vaccines) will be pharmaceutically acceptable. Immunogenic compositions typically contain components in addition to the antigen, for example, typically one or more pharmaceutical carriers, excipients, and / or adjuvants. A detailed discussion of carriers and excipients is available in Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987) Supplement 30, which is incorporated herein by reference. A detailed discussion of vaccine adjuvants is available in Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN 0-306-44867-X), which is incorporated herein by reference; and Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series), ISBN: 1-59259-083-7. Ed. O'Hagan.
[0134] The composition will generally be administered to mammals in aqueous form. However, prior to administration, the composition may be in a non-aqueous form. For example, some vaccines are manufactured in aqueous form, subsequently filled and dispensed, and administered in aqueous form, while other vaccines are lyophilized during manufacturing and reformulated into aqueous form at the time of use. In other words, the composition of the present invention may be a dried, e.g., lyophilized formulation. The composition may contain preservatives such as thiomersal or 2-phenoxyethanol. However, it is preferable that the vaccine be substantially mercury-free (i.e., less than 5 μg / mL), e.g., thiomersal-free. A mercury-free vaccine is more preferable. A preservative-free vaccine is particularly preferable. To improve thermal stability, the composition may contain a temperature protectant.
[0135] To control the tonicity, it is preferable to include physiological salts such as sodium salts. Sodium chloride (NaCl) is preferred and can be present at 1 to 20 mg / mL, for example, about 10 ± 2 mg / mL NaCl. Other possible salts include potassium chloride, potassium dihydrogen phosphate, anhydrous disodium phosphate, magnesium chloride, and calcium chloride.
[0136] The composition will generally have an osmotic pressure of 200 mOsm / kg to 400 mOsm / kg, preferably 240 to 360 mOsm / kg, and more preferably within the range of 290 to 310 mOsm / kg.
[0137] The composition may contain one or more buffering agents. Typical buffering agents include phosphate buffers; Tris buffers; borate buffers; succinate buffers; histidine buffers (especially with aluminum hydroxide adjuvants); or citrate buffers. The buffering agent will typically be included in a range of 5 to 20 mM.
[0138] The pH of the composition will generally be between 5.0 and 8.1, more typically between 6.0 and 8.0, for example, between 6.5 and 7.5, or between 7.0 and 7.8.
[0139] The composition is preferably sterile. The composition is preferably non-pyrogenic, for example, containing less than 1 EU (endotoxin units, a standard unit) per dose, preferably less than 0.1 EU per dose. The composition is preferably gluten-free.
[0140] The composition may contain materials for single-dose immunization or materials for multiple-dose immunization (i.e., a "multi-dose" kit). Preservative inclusion is preferred in multi-dose settings. Alternatively (or in addition to) including preservatives in multi-dose compositions, the composition may be placed in a container having a sterile adapter for material removal.
[0141] Human vaccines are typically administered in a dose volume of approximately 0.5 mL, but half the dose (i.e., approximately 0.25 mL) can be administered to children.
[0142] The immunogenic composition of the present invention may also contain one or more immunomodulators. Preferably, one or more of the immunomodulators contain one or more adjuvants.
[0143] Adjuvant The vaccines and immunogenic compositions of the present invention may also include adjuvants in addition to antigens. Adjuvants are used in the vaccine to enhance and modulate the immune response to the antigen. The adjuvants described herein may be combined with any of the antigens described herein.
[0144] The adjuvant may be any adjuvant known to those skilled in the art, but examples of adjuvants include (but are not limited to) oil-in-water emulsions (e.g., MF59 or AS03), liposomes, saponins, TLR2 agonists, TLR3 agonists, TLR4 agonists, TLR5 agonists, TLR6 agonists, TLR7 agonists, TLR8 agonists, TLR9 agonists, aluminum salts, nanoparticles, microparticles, immunostimulatory complexes (ISCOMs), calcium fluoride, and organic complex compounds or combinations thereof.
[0145] Oil-in-water emulsion Embodiments of the present invention provide a vaccine or immunogenic composition for use in the present invention, comprising an oil-in-water emulsion. The oil-in-water emulsion of the present invention comprises a metabolizable oil and an emulsifier. In order to make any oil-in-water composition suitable for human administration, the oil phase of the emulsion system must contain a metabolizable oil. The meaning of the term metabolizable oil is well known in the art. Metabolizable can be defined as "capable of being converted by metabolism" (Dorland's Illustrated Medical Dictionary, WB Sanders Company, 25th edition, 1974). A particularly preferred metabolizable oil is squalene. Squalene (2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene) is an unsaturated oil found in large quantities in shark liver oil and in relatively small quantities in olive oil, wheat germ oil, rice bran oil, and yeast, and is a particularly preferred oil for use in the oil-in-water emulsion of the present invention. Squalene is a metabolizable oil because it is an intermediate in the biosynthesis of cholesterol (Merck index, 10th edition, item number 8619). In some embodiments, if the vaccine or immunogenic composition of the present invention comprises an oil-in-water emulsion, the metabolizable oil is present in the vaccine or immunogenic composition in an amount of 0.5% to 10% (v / v) of the total volume of the composition. The oil-in-water emulsion further comprises an emulsifier. The emulsifier may preferably be polyoxyethylene sorbitan monooleate (POLYSORBATE 80). Furthermore, the emulsifier may preferably be present in the vaccine or immunogenic composition in an amount of 0.125% to 4% (v / v) of the total volume of the composition. The oil-in-water emulsion may optionally contain tocol, which is well known in the art and is described in European Patent No. 0382271B1. Preferably, the tocol may be α-tocopherol or a derivative thereof, such as α-tocopherol succinate (also known as vitamin E succinate). Preferably, the tocol is present in the adjuvant composition in an amount of 0.25% to 10% (v / v) of the total volume of the immunogenic composition.Oil-in-water emulsions may also optionally contain sorbitan trioleate (SPAN 85).
[0146] Methods for producing oil-in-water emulsions are well known to those skilled in the art. Generally, the method includes the steps of mixing an oil phase (optionally including tocol) with a surfactant such as PBS / TWEEN® 80 solution, and subsequently homogenizing using a homogenizer; it will be apparent to those skilled in the art that a method including the step of passing the mixture twice through a syringe needle is suitable for homogenizing small amounts of liquid. Similarly, the emulsification process in a microfluidizer (e.g., M110S microfluidic instrument, up to 50 passes, over 2 minutes with a maximum pressure input of 6 bar (output pressure of about 850 bar)) can be adapted by those skilled in the art to produce smaller or larger amounts of emulsion. Adaptation can be achieved by conventional experiments, including measuring the resulting emulsion until the preparation is achieved with oil droplets of the desired diameter.
[0147] In oil-in-water emulsions, the oil and emulsifier should be in an aqueous carrier. The aqueous carrier may be, for example, phosphate-buffered saline or citrate. In particular, the oil-in-water emulsion system used in the present invention has small oil droplet sizes in the range of less than a micron. Preferably, the droplet size will be in the range of 120 to 750 nm in diameter, more specifically 120 to 600 nm. More specifically, the oil-in-water emulsion contains oil droplets in which, based on strength, at least 70% are less than 500 nm in diameter, more specifically at least 80% are less than 300 nm in diameter, and more specifically at least 90% are in the range of 120 to 200 nm in diameter.
[0148] The oil droplet size, i.e., diameter, according to the present invention is given by intensity. There are several methods for determining the diameter of the oil droplet size by intensity. Intensity is measured by dynamic light scattering using a sizing instrument, preferably a Malvern Zetasizer 4000 or more preferably a Malvern Zetasizer 3000HS. The first possibility is to determine the z-mean diameter ZAD by dynamic light scattering (PCS-photon correlation spectroscopy); this method additionally gives the polydispersity index (PDI), and both ZAD and PDI are calculated using a cumulant algorithm. These values do not require knowledge of the particle refractive index. The second means is to calculate the diameter of the oil droplet by determining the overall particle size distribution using another algorithm, which is either Contin, or NNLS, or the automatic "Malvern" one (the default algorithm provided by the sizing instrument). In most cases, the particle refractive index of the composite composition is unknown, so only the intensity distribution and, if necessary, the intensity average derived from this distribution are considered.
[0149] ISCOM In some embodiments of the present invention, a vaccine or immunogenic composition of the present invention comprising ISCOM is provided. ISCOM is well known in the art (see Kersten & Crommelin, 1995, Biochimica et Biophysica Acta 1241: 117-138). ISCOM comprises saponins, cholesterol, and phospholipids and typically forms an open cage-like structure of about 40 nm in size. ISCOM arises from the interaction of saponins, cholesterol, and further phospholipids. A typical reaction mixture for the preparation of ISCOM is 5 mg / mL of saponin and 1 mg / mL each of cholesterol and phospholipids.Suitable phospholipids for use in ISCOM are, but are not limited to, phosphocholines (didecanoyl-L-α-phosphatidylcholine [DDPC], dilauroyl phosphatidylcholine [DLPC], dimyristoyl phosphatidylcholine [DMPC], dipalmitoyl phosphatidylcholine [DPPC], distearoyl phosphatidylcholine [DSPC], dioleoyl phosphatidylcholine [DOPC], 1-palmitoyl,2-oleoyl phosphatidylcholine [POPC], dierydoyl phosphatidylcholine [DEPC]), phosphoglycerols (1,2-dimeristoyl-sn-glycero-3-phosphoglycerol [DMPG], 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol [DPPG], 1,2-distearoyl-sn-glycero-3-phosphoglycerol [DSPG], 1-palmitoyl Examples include yl-2-oleoyl-sn-glycero-3-phosphoglycerol [POPG], phosphatidic acid (1,2-dimiristoyl-sn-glycero-3-phosphatidic acid [DMPA], dipalmitoylphosphatidic acid [DPPA], distearoyl-phosphatidic acid [DSPA]), phosphoethanolamine (1,2-dimiristoyl-sn-glycero-3-phosphoethanolamine [DMPE], 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine [DPPE], 1,2-distearoyl-sn-glycero-3-phosphoethanolamine [DSPE], 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine [DOPE]), phosphoserine, and polyethylene glycol [PEG] phospholipids (mPEG-phospholipids, polyglycerol-phospholipids, functionalized phospholipids, terminally activated phospholipids). In certain embodiments, ISCOM comprises 1-palmitoyl-2-oleoyl-glycero-3-phosphoethanolamine. In further specific embodiments, highly purified phosphatidylcholine is used and can be selected from the group consisting of phosphatidylcholine (egg-derived), hydrogenated phosphatidylcholine (egg-derived), phosphatidylcholine (soybean-derived), and hydrogenated phosphatidylcholine (soybean-derived). In further specific embodiments, ISCOM comprises phosphatidylethanolamine [POPE] or a derivative thereof.Numerous saponins are suitable for use in ISCOM. The adjuvant and hemolytic activities of individual saponins have been extensively studied in the art. For example, Quil A (derived from the bark of the South African tree Quillaya Saponaria Molina) and its fraction are described in U.S. Patent No. 5,057,540 and “Saponins as vaccine adjuvants”, Kensil, CR, Crit. Rev. Ther. Drug. Carrier Syst., 1996, 12 (1-2): 1-55; and European Patent No. 0362279B1. ISCOM containing the Quil A fraction has been used in vaccine production (European Patent No. 0109942B1). These structures have been reported to possess adjuvant activity (European Patent No. EP0109942B1; International Publication No. 96 / 11711). Fractions of QuilA, derivatives of QuilA, and / or combinations thereof are suitable saponin preparations for use in ISCOM. The hemolytic saponins QS21 and QS17 (HPLC-purified fractions of Quil A) are described as potent adjuvants, and their methods of production are disclosed in U.S. Patent No. 5,057,540 and European Patent No. 0362279B1. The use of QS7 (non-hemolytic fraction of Quil-A) as a potent adjuvant for systemic vaccines is also described in these references. The use of QS21 is further described in Kensil et al. (1991. J. Immunology vol 146, 431-437). Combinations of QS21 with polysorbate or cyclodextrin are known (International Publication No. 99 / 10008). Particulate adjuvant systems containing QuilA fractions such as QS21 and QS7 are described in International Publications 96 / 33739 and 96 / 11711, and are incorporated herein by reference. Other specific QuilA fractions designated as QH-A, QH-B, and QH-C, as well as mixtures of QH-A and QH-C designated as QH-703, are disclosed in International Publication 96 / 011711 in the form of ISCOM, and are incorporated herein by reference.
[0150] fine particles In some embodiments of the present invention, vaccines or immunogenic compositions of the present invention comprising microparticles are provided. Microparticles, compositions comprising microparticles, and methods for producing microparticles are well known in the art (see Singh et al. [2007 Expert Rev. Vaccines 6(5): 797-808] and International Publication No. 98 / 033487). As used herein, the term “microparticles” means particles with a diameter or length of about 10 nm to about 10,000 μm, derived from polymer materials having various molecular weights and, in the case of copolymers such as PLG, various lactide:glycolide ratios. In particular, microparticles would be of a diameter that allows for parenteral administration to a subject without clogging the administration device and / or the capillaries of the subject. Microparticles are also known as microspheres. Microparticle size is readily determined by techniques well known in the art, such as photon correlation spectroscopy, laser diffraction, and / or scanning electron microscopy. Microparticles for use herein would be formed from materials that are sterilizable, non-toxic, and biodegradable. Examples of such materials, though not limited to them, include poly(α-hydroxy acids), polyhydroxybutyric acid, polycaprolactone, polyorthoesters, and polyanhydrides.
[0151] Liposomes In some embodiments of the present invention, a vaccine or immunogenic composition comprising liposomes is provided. The term “liposome” generally refers to a monolayer or multilayer (in particular, 2, 3, 4, 5, 6, 7, 8, 9, or 10 layers, depending on the number of lipid membranes formed) lipid structure that encapsulates an aqueous interior. Liposomes and liposome formulations are well known in the art. Lipids capable of forming liposomes include all substances having fat and fat-like properties. Lipids that can constitute the lipids in liposomes can be selected from the group consisting of glycerides, glycerophospholipids, glycerophosphinolipids, glycerophosphonolipids, sulfolipids, sphingolipids, phospholipids, isoprenolides, steroids, stearin, sterols, archeolipids, synthetic cationic lipids, and carbohydrate-containing lipids. Liposome size can vary from 30 nm to several μm, depending on the phospholipid composition and the method used for their preparation. In certain embodiments of the present invention, the liposome size may be in the range of 50 nm to 500 nm, and in further embodiments, in the range of 50 nm to 200 nm. Dynamic laser light scattering is a method used to measure the size of liposomes, which is well known to those skilled in the art. The liposomes preferably contain neutral lipids, such as phosphatidylcholine, e.g., egg yolk phosphatidylcholine, dioleoyl phosphatidylcholine (DOPC), or dilauryl phosphatidylcholine, which are preferably amorphous at room temperature. In certain embodiments, the liposomes of the present invention contain DOPC. The liposomes may also contain charged lipids that increase the stability of the liposome-saponin structure with respect to liposomes composed of saturated lipids. In these cases, the amount of charged lipids is preferably 1 to 20% (w / w), more preferably 5 to 10%. The ratio of sterols to phospholipids is 1 to 50% (mol / mol), more preferably 20 to 25% (mol / mol).
[0152] saponin In some embodiments of the present invention, the vaccine or immunogenic composition of the present invention comprises a saponin. Saponins particularly suitable for use in the present invention are Quil A and its derivatives. Quil A is a saponin preparation isolated from the South African tree Quillaja saponaria molina, and its adjuvant activity was first described in 1974 by Dalsgaard et al. ("Saponin adjuvants", Archiv. fur die gesamte Virusforschung, Vol. 44, Springer Verlag, Berlin, pp. 243-254). Purified fractions of Quil A that retain adjuvant activity without the toxicity associated with Quil A, such as QS7 and QS21 (also known as QA7 and QA21), have been isolated by HPLC (EP0362278). QS-21 is a natural saponin derived from the bark of Quillaja saponaria molina, and is CD8 + The saponin in question is a saponin that induces a cytotoxic T cell (CTL), Th1 cell, and dominant IgG2a antibody response, and is specific to the context of the present invention. The saponin adjuvant in the immunogenic composition of the present invention is, in particular, an immunologically active fraction of Quil A, such as QS-7 or QS-21, preferably QS-21. In certain embodiments, the vaccine and / or immunogenic composition of the present invention contains an immunologically active saponin fraction in a substantially pure form. In particular, the vaccine or immunogenic composition of the present invention contains QS21 in a substantially pure form, i.e., QS21 is at least 75%, 80%, 85%, 90% pure, for example, at least 95% pure, or at least 98% pure.
[0153] In certain embodiments, QS21 is provided with an exogenous sterol, such as cholesterol. Suitable sterols include β-sitosterol, stigmasterol, ergosterol, ergocalciferol, and cholesterol. In further specific embodiments, the adjuvant composition contains cholesterol as the sterol. These sterols are well known in the art; for example, cholesterol is disclosed in the Merck Index, 11th edition, page 341, as a naturally occurring sterol found in animal fats.
[0154] In one embodiment, the liposomes of the present invention containing saponins preferably contain neutral lipids, such as phosphatidylcholine, e.g., egg yolk phosphatidylcholine, dioleoyl phosphatidylcholine (DOPC), or dilauryl phosphatidylcholine, which are preferably amorphous at room temperature. The liposomes may also contain charged lipids that increase the stability of the liposome-QS21 structure relative to liposomes composed of saturated lipids. In these cases, the amount of charged lipids is preferably 1-20% (w / w), particularly 5-10%. The ratio of sterols to phospholipids is 1-50% (mol / mol), preferably 20-25% (mol / mol).
[0155] When the active saponin fraction is QS21, the QS21:sterol ratio is typically 1:100 to 1:1 (w / w), preferably 1:10 to 1:1 (w / w), and more preferably around 1:5 to 1:1 (w / w). Preferably, there is an excess of sterols, and the QS21:sterol ratio is at least 1:2 (w / w). In one embodiment, the QS21:sterol ratio is 1:5 (w / w). The sterol is preferably cholesterol.
[0156] Other useful saponins are derived from horse chestnut (Aesculus hippocastanum) or Gyophila struthium. Other saponins described in the literature include escin, listed in the Merck Index (12th edition: item 3737) as a mixture of saponins present in the seeds of horse chestnut (Aesculus hippocastanum). Its isolation by chromatography and purification (Fiedler, Arzneimittel-Forsch. 4, 213 (1953)) and by ion exchange resin (Erbring et al., U.S. Patent No. 3,238,190) has been described. The escin fraction has been purified and shown to be biologically active (Yoshikawa et al., 1996, Chem Pharm Bull (Tokyo), 44(8): 1454-1464). Sapoalbin derived from Gypsophila struthium (R. Vochten et al., 1968, J. Pharm. Belg. 42: p213-226) has also been described, for example, in relation to ISCOM production.
[0157] Saponins such as QS21 can be used in amounts of 1 to 100 μg per human dose of the adjuvant composition. QS21 can be used at levels of about 50 μg, for example, 40 to 60 μg, preferably 45 to 55 μg, 49 to 51 μg, or 50 μg. In further embodiments, the human dose of the adjuvant composition contains QS21 at levels of about 25 μg, for example, 20 to 30 μg, preferably 21 to 29 μg, 22 to 28 μg, 28 to 27 μg, 24 to 26 μg, or 25 μg.
[0158] TLR4 Agonist In some embodiments, the vaccine or immunogenic composition of the present invention comprises a TLR4 agonist. “TLR agonist” means a component capable of inducing a signaling response via the TLR signaling pathway, either directly as a ligand or indirectly through the generation of endogenous or exogenous ligands (Sabroe et al, 2003, JI p1630-5). TLR4 agonists are capable of inducing a signaling response via the TLR-4 signaling pathway. Preferred examples of TLR4 agonists are lipopolysaccharides, preferably non-toxic derivatives of lipid A, particularly monophosphoryl lipid A, or more specifically, 3-deacylated monophosphoryl lipid A (3D-MPL).
[0159] 3D-MPL is marketed by GlaxoSmithKline Biologicals under the name MPL and will be referred to as MPL or 3D-MPL throughout this document. See, for example, U.S. Patents 4,436,727; 4,877,611; 4,866,034 and 4,912,094. 3D-MPL is a CD4 having the IFN-γ(Th1) phenotype. + It primarily promotes T cell responses. 3D-MPL can be produced according to the method disclosed in UK Patent Application Publication 2 220 211A. Chemically, 3D-MPL is a mixture of 3-deacylated monophosphoryl lipid A having 4, 5, or 6 acylated chains. In the compositions of the present invention, small particle 3D-MPL can be used to prepare aqueous adjuvant compositions. Small particle 3D-MPL has a particle size that can be sterile filtered through a 0.22 μm filter. Such preparations are described in International Publication 94 / 21292. Preferably, powdered 3D-MPL is used to prepare the aqueous adjuvant compositions of the present invention.
[0160] Other TLR-4 agonists that can be used are alkyl glucosaminide phosphates (AGPs), such as those disclosed in International Publication No. 98 / 50399 or U.S. Patent No. 6,303,347 (which also discloses a process for the preparation of AGPs), preferably pharmaceutically acceptable salts of AGPs as disclosed in RC527 or RC529 or U.S. Patent No. 6,764,840.
[0161] Other suitable TLR-4 agonists are compounds I, II, and III disclosed on pages 4-5 of International Publication 03 / 011223 or pages 3-4 of International Publication 03 / 099195, particularly compounds disclosed in International Publication 03 / 011223 as ER803022, ER803058, ER803732, ER804053, ER804057m, ER804058, ER804059, ER804442, ER804680, and ER804764, as described in International Publications 03 / 011223 and 03 / 099195. For example, one suitable TLR-4 agonist is ER804057.
[0162] TLR-4 agonists such as lipopolysaccharides like 3D-MPL can be used in amounts of 1 to 100 μg per human dose of the adjuvant composition. 3D-MPL can be used at levels of approximately 50 μg per human dose, for example, 40 to 60 μg, preferably 45 to 55 μg, 49 to 51 μg, or 50 μg. In further embodiments, the human dose of the adjuvant composition contains 3D-MPL at levels of approximately 25 μg, for example, 20 to 30 μg, preferably 21 to 29 μg, 22 to 28 μg, 28 to 27 μg, 24 to 26 μg, or 25 μg.
[0163] Synthetic derivatives of lipid A are known and not limited to the following, but are considered to be TLR 4 agonists: OM174(2-deoxy-6-o-[2-deoxy-2-[(R)-3-dodecanoyloxytetradecanoylamino]-4-o-phosphono-β-D-glucopyranosyl]-2-[(R)-3-hydroxytetradecanoylamino]-α-D-glucopyranosyldihydrogen phosphate), (International Publication No. 95 / 14026) OM294 DP (3S, 9 R)-3--[(R)-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9(R)-[(R)-3-hydroxytetradecanoylamino]decane-1,10-diol,1,10-bis(dihydrogenophosphate) (International Publication Nos. 99 / 64301 and 00 / 0462) OM197 MP-Ac DP (3S-, 9R)-3-[(R)-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]decane-1,10-diol,1-dihydrogenophosphate 10-(6-aminohexanoate) (International Publication No. 01 / 46127) PHAD (phosphorylated hexaacyl disaccharide).
[0164] Other suitable TLR-4 ligands capable of inducing a TLR-4-mediated signaling response (Sabroe et al, JI 2003 p1630-5) include, for example, lipopolysaccharides and their derivatives or fragments derived from Gram-negative bacteria, particularly non-toxic derivatives of LPS (such as 3D-MPL). Other suitable TLR agonists include: heat shock proteins (HSPs) 10, 60, 65, 70, 75, or 90; surfactant protein A, hyaluronane oligosaccharides, heparan sulfate fragments, fibronectin fragments, fibrinogen peptides, and β-defensin-2, muramyl dipeptide (MDP), or F protein of respiratory syncytial virus (RSV). In one embodiment, the TLR agonist is HSP 60, 70, or 90.
[0165] TLR Agonist Instead of TLR4 agonists, other natural or synthetic agonists of TLR molecules may be used in the vaccine or immunogenic composition of the present invention. These include, but are not limited to, agonists for TLR2, TLR3, TLR5, TLR6, TLR7, TLR8, and TLR9.
[0166] In one embodiment of the present invention, a TLR agonist capable of inducing a TLR-1-mediated signal transduction response is used (Sabroe et al, JI 2003 p1630-5). Preferably, the TLR agonist capable of inducing a TLR-1-mediated signal transduction response is selected from: triacylated lipopeptides (LP); phenol-soluble modulin; Mycobacterium tuberculosis LP; S-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys(4)-OH, trihydrochloride (Pam3Cys)LP, which mimics the acetylated amino terminus of bacterial lipoproteins and OspA LP derived from Borrelia burgdorferi.
[0167] In further embodiments, TLR agonists capable of inducing a TLR-2-mediated signaling response are used (Sabroe et al, JI 2003 p1630-5). Preferably, TLR agonists capable of inducing a TLR-2-mediated signaling response are one or more of the following: lipoproteins, peptidoglycans, bacterial lipopeptides derived from Mycobacterium tuberculosis, B. burgdorferi, T. pallidum, peptidoglycans derived from species including Staphylococcus aureus, lipoteichoic acid, mannuronic acid, Neisseria porins, bacterial pili, Yersinia toxic factors, CMV virion, measles hemagglutinin, and yeast-derived zymosan.
[0168] In further embodiments, TLR agonists capable of inducing a TLR-3-mediated signaling response are used (Sabroe et al, JI 2003 p1630-5). Preferably, the TLR agonists capable of inducing a TLR-3-mediated signaling response are double-stranded RNA (dsRNA), or polyinosinate-polycytidylic acid (Poly IC), molecular nucleic acid patterns associated with viral infection.
[0169] In alternative embodiments, TLR agonists capable of inducing a TLR-5 mediated signaling response are used (Sabroe et al, JI 2003 p1630-5). Preferably, the TLR agonist capable of inducing a TLR-5 mediated signaling response is bacterial flagellin. The TLR-5 agonist may be flagellin or a fragment of flagellin that retains TLR-5 agonist activity. Flagellins include polypeptides selected from the group consisting of H. pylori, Salmonella typhimurium, Vibrio cholerae, Serratia marcescens, Shigella flexneri, Treponema pallidum, L. pneumophila, B. burgdorferi; C. difficile, R. meliloti, A. tumefaciens; R. lupine; B. clarridgeiae, P. mirabilis, B. subtilis, L. moncytogenes, P. aeruginosa, and Escherichia coli.
[0170] In certain embodiments, flagellin is selected from the group consisting of Salmonella typhimurium flagellin B (Genbank registration number AF045151), fragments of Salmonella typhimurium flagellin B, Escherichia coli FliC (Genbank registration number AB028476); fragments of Escherichia coli FliC; Salmonella typhimurium flagellin FliC (ATCC14028); and fragments of Salmonella typhimurium flagellin FliC.
[0171] In further specific embodiments, the TLR-5 agonist is a cleaved flagellin as described in International Publication No. 09 / 156405, i.e., one in which the hypervariable domain is deleted. In one aspect of this embodiment, the TLR-5 agonist is FliC Δ174-400 FliC Δ161-405 and FliC Δ138-405 Selected from the group consisting of .
[0172] In further specific embodiments, the TLR-5 agonist is flagellin as described in International Publication No. 09 / 128950. In further embodiments, a TLR agonist capable of inducing a TLR-6 mediated signaling response is used (Sabroe et al, JI 2003 p1630-5). Preferably, TLR agonists capable of inducing a TLR-6 mediated signaling response are Mycobacteria lipoproteins, niacylated LPs, and phenol-soluble modulins. Further TLR-6 agonists are described in International Publication No. 03 / 043572.
[0173] In further embodiments, TLR agonists capable of inducing a TLR-7-mediated signaling response are used (Sabroe et al, JI 2003 p1630-5). Preferably, TLR agonists capable of inducing a TLR-7-mediated signaling response are single-stranded RNA (ssRNA), loxoribine, guanosine analogs at the N7 and C8 positions, or imidazoquinoline compounds or derivatives thereof. In certain embodiments, the TLR agonist is imiquimod. Further TLR7 agonists are described in International Publication No. 02 / 085905.
[0174] In further embodiments, TLR agonists capable of inducing a TLR-8-mediated signaling response are used (Sabroe et al, JI 2003 p1630-5). Preferably, TLR agonists capable of inducing a TLR-8-mediated signaling response are single-stranded RNA (ssRNA), imidazoquinoline molecules with antiviral activity, such as reximod (R848); reximod is also recognizable by TLR-7. Other TLR-8 agonists that can be used are those described in International Publication No. 04 / 071459.
[0175] In further embodiments, TLR agonists capable of eliciting a signaling response are used, such as those containing a CpG motif. The term “immunostimulatory oligonucleotide” is used herein to mean an oligonucleotide capable of activating components of the immune system. In one embodiment, the immunostimulatory oligonucleotide contains one or more unmethylated cytosine-guanosine (CpG) motifs. In further embodiments, the immunostimulatory oligonucleotide contains one or more unmethylated thymidine-guanosine (TG) motifs or may be T-rich. T-rich means that the nucleotide composition of the oligonucleotide contains more than 50, 60, 70, or 80% thymidine. In one embodiment, the oligonucleotide is not an immunostimulatory oligonucleotide and does not contain an unmethylated CpG motif. In further embodiments, the immunostimulatory oligonucleotide is not T-rich and / or does not contain an unmethylated TG motif.
[0176] Oligonucleotides can be modified to improve their in vitro and / or in vivo stability. For example, in one embodiment, an oligonucleotide is modified to include a phosphorothioate skeleton, i.e., internucleotide linkages. Other suitable modifications, including diphosphorothioate, phosphoramidate, and methylphosphonate modifications, as well as alternative internucleotide linkages for oligonucleotides, are well known to those skilled in the art and are included in the present invention.
[0177] In another embodiment, the vaccine or immunogenic composition of the present invention further comprises an immunostimulator selected from the group consisting of TLR-1 agonists, TLR-2 agonists, TLR-3 agonists, TLR-4 agonists, TLR-5 agonists, TLR-6 agonists, TLR-7 agonists, TLR-8 agonists, TLR-9 agonists, or combinations thereof.
[0178] Calcium composite materials In some embodiments, the vaccine or immunogenic composition of the present invention comprises a calcium fluoride composite material containing Ca, F, and Z. “Z” as used herein means an organic molecule. “Composite material” as used herein is a material that exists as a solid when dry and is insoluble or sparingly soluble in pure water. In some embodiments, Z comprises a functional group that forms an anion when ionized. Such functional groups include, but are not limited to, one or more functional groups selected from the group consisting of hydroxyl, hydroxylate, hydroxo, oxo, N-hydroxylate, hydroxamate, N-oxide, bicarbonate, carbonate, carboxylate, fatty acid, thiolate, organophosphate, dihydrogenophosphate, monohydrogenophosphate, monoester of phosphoric acid, diester of phosphoric acid, phospholipid ester, phosphoolothioate, sulfate, bisulfate, enolate, ascorbate, phosphoascorbate, phenolate, and imine-olate.
[0179] In some embodiments, the calcium fluoride composite materials described herein include Z, which is an anionic organic molecule that has an affinity for calcium and forms a water-insoluble composite material together with calcium and fluorine. In a further embodiment, the calcium fluoride composite material described herein comprises Z, where Z is hydroxyl, hydroxylate, hydroxo, oxo, N-hydroxylate, hydroxamate, N-oxide, bicarbonate, carbonate, carboxylate and dicarboxylate, salt of carboxylic acid, salt of QS21, extract of Quillaja saponaria bark, extract of immunologically active saponins, salt of saturated or unsaturated fatty acids, salt of oleic acid, salt of amino acids, thiolate, thiolactate, salt of thiol compounds, salt of cysteine, salt of N-acetylcysteine, L-2-oxo-4-thiazolidine carboxylate, phosphate, dihydrogen phosphate, monohydrogen phosphate, salt of phosphate, monoester of phosphate and its salts, diester of phosphate and its salts, 3-O-desacyl-4'- It can be classified as including members of a chemical classification selected from the group consisting of monophosphoryl lipid A esters, 3D-MLA esters, MPL, phospholipid esters, DOPC, dioleolyphosphatidic derivatives, phosphates derived from CpG motifs, phosphorothioates, sulfates, bisulfates, sulfate salts, enolates, ascorbic acid, phosphoascorbic acid, phenolate, α-tocopherol, imine-olate, cytosine, methylcytosine, uracil, thymine, barbiturates, hypoxanthine, inosine, guanine, guanosine, 8-oxo-adenine, xanthine, uric acid, pteroic acid, pteroylglutamic acid, folic acid, riboflavin, and lumiflavin. In a further embodiment, the calcium fluoride composite material described herein comprises Z, which is selected from the group consisting of N-acetylcysteine; thiolactate; adipate; carbonate; folic acid; glutathione; and uric acid. In a certain embodiment, the calcium fluoride composite material described herein comprises Z, which is selected from the group consisting of N-acetylcysteine; adipate; carbonate; and folic acid.In a further embodiment, the calcium fluoride composite material herein comprises Z, where Z is N-acetylcysteine, and the composite material comprises from 51% Ca, 48% F, and 1% or less of N-acetylcysteine (w / w) to 37% Ca, 26% F, and 37% N-acetylcysteine (w / w). In a further embodiment, the calcium fluoride composite material herein comprises Z, where Z is a thiolactate, and the composite material comprises from 51% Ca, 48% F, and 1% or less of thiolactate (w / w) to 42% Ca, 30% F, and 28% thiolactate (w / w). In a further embodiment, the calcium fluoride composite material herein comprises Z, where Z is an adipine, and the composite material comprises from 51% Ca, 48% F, and 1% or less of adipine (w / w) to 38% Ca, 27% F, and 35% adipine (w / w). In a further embodiment, the calcium fluoride composite material herein contains Z, where Z is a carbonate, and the composite material comprises a composition ranging from 51% Ca, 48% F, and 1% or less of carbonate (w / w) to 48% Ca, 34% F, and 18% carbonate (w / w). In a further embodiment, the calcium fluoride composite material herein contains Z, where Z is folic acid, and the composite material comprises a composition ranging from 51% Ca, 48% F, and 1% or less of folic acid (w / w) to 22% Ca, 16% F, and 62% folic acid (w / w). In a further embodiment, the calcium fluoride composite material herein contains Z, where Z is glutathione, and the composite material comprises a composition ranging from 51% Ca, 48% F, and 1% or less of glutathione (w / w) to 28% Ca, 20% F, and 52% glutathione (w / w). In a further embodiment, the calcium fluoride composite material herein comprises Z, where Z is uric acid, and the composite material comprises a composition ranging from 51% Ca, 48% F, and 1% or less uric acid (w / w) to 36% Ca, 26% F, and 38% uric acid (w / w).
[0180] Aluminum salt In one embodiment, the vaccine or immunogenic composition of the present invention comprises an aluminum salt. Suitable aluminum salt adjuvants are well known to those skilled in the art and include, but are not limited to, aluminum phosphate, aluminum hydroxide, or combinations thereof. Suitable aluminum salt adjuvants include, but are not limited to, REHYDRAGEL HS, ALHYDROGEL 85, REHYDRAGEL PM, REHYDRAGEL AB, REHYDRAGEL HPA, REHYDRAGEL LV, ALHYDROGEL, or combinations thereof.
[0181] In particular, aluminum salts may have protein adsorption capacities of 2.5–3.5, 2.6–3.4, 2.7–3.3, or 2.9–3.2, 2.5–3.7, 2.6–3.6, 2.7–3.5, or 2.8–3.4 mg of protein (BSA) / mL of aluminum salt. In certain embodiments of the present invention, the aluminum salt has a protein adsorption capacity of 2.9–3.2 mg BSA / mg of aluminum salt. The protein adsorption capacity of an aluminum salt can be measured by any means known to those skilled in the art. The protein adsorption capacity of an aluminum salt can be measured using the method described in Example 1 of International Publication No. 12 / 136823 (using BSA) or a variation thereof.
[0182] The aluminum salts described herein (i.e., having the protein adsorption capacity described herein) may have crystal sizes of 2.8 to 5.7 nm as measured by X-ray diffraction, for example, 2.9 to 5.6 nm, 2.8 to 3.5 nm, 2.9 to 3.4 nm, or 3.4 to 5.6 nm or 3.3 to 5.7 nm as measured by X-ray diffraction. X-ray diffraction is well known to those skilled in the art. In certain embodiments of the present invention, the crystal size is measured using the method or a variation thereof described in Example 1 of International Publication No. 12 / 136823.
[0183] Polypeptides and / or nucleic acids described herein can be administered to a subject by any of the following routes of administration, for example, orally, intranasally, sublingually, intravenously, intramuscularly, intradermally (e.g., skin patches using microprojection), or transdermally (e.g., ointments or creams).
[0184] A seventh aspect of the present invention provides a polypeptide as defined in the first aspect, a nucleic acid as defined in the second aspect, a vector as defined in the third aspect, and / or a vaccine as defined in the sixth aspect, for pharmaceutical use.
[0185] The eighth aspect provides polypeptides as defined in the first aspect, nucleic acids as defined in the second aspect, vectors as defined in the third aspect, and / or vaccines as defined in the sixth aspect for use in inducing an immune response in mammals, for example, to treat and / or prevent one or more diseases.
[0186] The ninth aspect provides the use of polypeptides as defined in the first aspect, nucleic acids as defined in the second aspect, vectors as defined in the third aspect, and / or vaccines as defined in the sixth aspect for inducing an immune response in mammals, for example, for treating and / or preventing one or more diseases.
[0187] A tenth aspect provides the use of polypeptides as defined in the first aspect, nucleic acids as defined in the second aspect, vectors as defined in the third aspect, and / or vaccines as defined in the sixth aspect for producing an immune response in mammals, for example, for the manufacture of a medicament for treating and / or preventing one or more diseases.
[0188] An eleventh aspect provides a method for inducing an immune response in a mammal, comprising or comprising the step of administering to a mammal an effective amount of a polypeptide as defined in the first aspect, a nucleic acid as defined in the second aspect, a vector as defined in the third aspect, and / or a vaccine as defined in the sixth aspect.
[0189] In any one of the seventh to eleventh embodiments or methods, one or more diseases are urinary tract infections (UTIs). Alternatively or additionally, the UTI is caused by one or more bacteria of a genera selected from the group consisting of Escherichia and Klebsiella. Alternatively or additionally, one or more bacteria are selected from the group consisting of Escherichia coli and Klebsiella pneumoniae. Alternatively or additionally, Escherichia coli is urinary tract pathogenic Escherichia coli (UPEC). Alternatively or additionally, one or more bacteria are selected from the group consisting of Escherichia coli J96, Escherichia coli UPEC 536, Escherichia coli CFT073, Escherichia coli UMN026, Escherichia coli clone Di14, Escherichia coli clone Di2, Escherichia coli CFT073; Escherichia coli IA139, Escherichia coli 536, Escherichia coli NA114, and Escherichia coli UTI89. Alternatively or additionally, one or more bacteria may be selected from the following group of K. pneumoniae strains: C3091, 3824, 3857, 3858, 3859, 3860, 3861, 3928, 3950, 3951, 4041, 4121, 4133, sp3, sp7, sp10, sp13, sp14, sp15, sp19, sp20, sp22, sp25, sp28, sp29, sp30, sp31, sp32, sp33, sp34, sp37, sp39, sp41, cas119, c as120, cas121, cas122, cas123, cas124, cas125, cas126, cas127, cas128, cas663, cas664, cas665, cas666, cas667, cas668, cas669, cas670, cas671, cas672, cas673, cas674, cas675, cas676, cas677, cas678, cas679, cas680, cas681, cas682, Kp342 and MGH78578.
[0190] Preferred non-limiting examples embodying specific aspects of the present invention are described herein with reference to the following tables and drawings. [Brief explanation of the drawing]
[0191] [Figure 1A]This figure shows a schematic representation of the FimH construct. (A) Structure of stabilized FimH (PDB: 4XO9). Cartoon representation of FimH stabilized by the FimGFimG donor chain (blue, indicated by arrows). The FimHL domain is yellow (upper part) and the FimHP domain is red (lower part). The glycine natural linker between domains is represented by green bars. [Figure 1B] This figure shows a schematic representation of the FimH construct. (B) Structure of FimH_DG_PGDGN_ferritin. Amino acid sequence of FimH_DG_PGDGN (light blue) fused to ferritin (red). A linker composed of SGS-8H-GSG- links FimH to the ferritin molecule. The IgK leader sequence for expression and secretion into the culture medium in mammalian cells is yellow, followed by an additional N-terminal charged residue. 3D structural model obtained using Rosetta common software. Cartoon representation of FimH_DG presented on the ferritin surface. There are 24 FimH subunits, colored yellow / blue, and ferritin is colored red. [Figure 2A-1] This figure shows that the expression of FimH nanoparticles in E. coli leads to inclusion body formation. (A) SDS-PAGE analysis of E. coli cytoplasmic expression of FimH_DG_(GSG4)-ferritin, FimHL cys-cys_Qβ, FimHL cys-cys_mI3 and FimHL-NOcys-MI3 in heated and reduced samples. The constructs are expressed but can only be detected in the insoluble fraction (urea 8M, U8M) and not in the soluble fraction (sol). The protein is undetectable in the total lysate fraction (Tot) due to insolubility; accumulation of insoluble material can be detected at the top of the gel. Anti-His Western blotting of E. coli cytoplasmic expression of FimHL-Nocys-MI3 in heated and reduced samples. Mutations in the internal disulfide crosslinks in the FimHL domain did not improve solubility, as only a faint band was detected in the soluble fraction. [Figure 2A-2]This figure shows that the expression of FimH nanoparticles in E. coli leads to inclusion body formation. (A) SDS-PAGE analysis of E. coli cytoplasmic expression of FimH_DG_(GSG4)-ferritin, FimHL cys-cys_Qβ, FimHL cys-cys_mI3 and FimHL-NOcys-MI3 in heated and reduced samples. The constructs are expressed but can only be detected in the insoluble fraction (urea 8M, U8M) and not in the soluble fraction (sol). The protein is undetectable in the total lysate fraction (Tot) due to insolubility; accumulation of insoluble material can be detected at the top of the gel. Anti-His Western blotting of E. coli cytoplasmic expression of FimHL-Nocys-MI3 in heated and reduced samples. Mutations in the internal disulfide crosslinks in the FimHL domain did not improve solubility, as only a faint band was detected in the soluble fraction. [Figure 2A-3] This figure shows that the expression of FimH nanoparticles in E. coli leads to inclusion body formation. (A) SDS-PAGE analysis of E. coli cytoplasmic expression of FimH_DG_(GSG4)-ferritin, FimHL cys-cys_Qβ, FimHL cys-cys_mI3 and FimHL-NOcys-MI3 in heated and reduced samples. The constructs are expressed but can only be detected in the insoluble fraction (urea 8M, U8M) and not in the soluble fraction (sol). The protein is undetectable in the total lysate fraction (Tot) due to insolubility; accumulation of insoluble material can be detected at the top of the gel. Anti-His Western blotting of E. coli cytoplasmic expression of FimHL-Nocys-MI3 in heated and reduced samples. Mutations in the internal disulfide crosslinks in the FimHL domain did not improve solubility, as only a faint band was detected in the soluble fraction. [Figure 2B] This figure shows that the expression of FimH nanoparticles in E. coli leads to inclusion body formation. (B) SDS-PAGE analysis of E. coli periplasmic expression of FimHL-MI3 and cytoplasmic FimHL-ferritin. Bands corresponding to FimHL-MI3 and ferritin fusions were detected in the total lysate and insoluble fraction (U8M). [Figure 3] This figure shows the prediction of the N-glycosylation FimH site using NetNGly prediction software. [Figure 4] This figure shows the expression of stabilized FimH constructs (FimH_ΔGG_PGDGN_DG: 930SI;FimH_DNKQ_DG: 931SI;FimH_PGDGN_DG: 932SI) and the FimHC complex in mammalian cells. [Figure 5] This figure shows the Western blot analysis of mammalian expression constructs containing the additional N-terminal amino acids. (A) Figure 5A: Bands corresponding to FIMH nanoparticles were detected only for FIMH_DG_PGDGN-ferritin (995SI) 3 and 6 days after transfection. (B) Figure 5B: Cartoon representation of FimH from strain 536, with three different residues highlighted and represented by bars compared to J96. (C) Figure 5C: PNGase treatment of FIMH_DG_PGDGN_IMX313 and FIMH_DG_PGDGN_ferritin from strain J96. After treatment, a shift of FIMH_DG_PGDGN_IMX313 was obtained in the correct MW, suggesting that the protein is glycosylated in mammalian cells. FIMH_DG_PGDGN_ferritin from strain J96 was not detected in either the untreated or treated PNGase samples, suggesting that this protein is degraded. [Figure 6-1] This figure shows the MS-Spec peptide mapping. [Figure 6-2] This figure shows the MS-Spec peptide mapping. [Figure 6-3] This figure shows the MS-Spec peptide mapping. [Figure 6-4] This figure shows the MS-Spec peptide mapping. [Figure 7] This figure shows the expression of candidate amino acids without additional N-terminal amino acids by Western blotting. [Figure 8A] This figure shows candidate cryo-EM NS-EM (negative staining) with or without additional AA at the N-terminus. [Figure 8B]This figure shows candidate cryo-EM NS-EM (negative staining) with or without additional AA at the N-terminus. [Figure 8C] This figure shows candidate cryo-EM NS-EM (negative staining) with or without additional AA at the N-terminus. [Figure 8D] This figure shows candidate cryo-EM NS-EM (negative staining) with or without additional AA at the N-terminus. [Figure 9] This figure shows candidate cryo-EM NS-EM (negative staining) of strains that do not contain additional amino acids at the N-terminus. (A) Figure 9A: Negative staining micrograph of 1095SI FIMHL-ferritin (strain 536) that does not contain additional amino acids. (B) Figure 9B: Negative staining micrograph of FIMHL-MI3 (strain J96) that does not contain additional amino acids. (C) Figure 9C: Negative staining micrograph of 1184SI FIMH_DG_PGDGN_536-encapsulin that does not contain additional amino acids. [Figure 10] This figure shows that the 3D map reveals the presence of three "anchor-like" appendages on three rotation axes. [Figure 11] This figure shows the measurement of IgG titers by ELISA assay. Mouse serum was tested 21 days after vaccination (after dose I, green), 35 days after vaccination (after dose II, blue), and 45 days after vaccination (after dose III, red). FimHL produced by E. coli was used as the ELISA plate coating. [Figure 12]Figure showing the bacterial inhibition assay (BAI) against SV-HUC cells. Microscopic observation analysis (OPERA Phenix) and bacterial adhesion measured by SV-HUC (ATCC) cells were used. The fluorescence volume or area (μm3 or 2) of adherent bacteria was used as the readout. A pool of sera raised against recombinant proteins FimHC, FimHL-cys (purified from Escherichia coli) was used as a control. A pool of sera raised against recombinant proteins FimH_PGDGN_DG (932SI), FimH_DNKQ_DG (931SI), FimH_DNKQ_DG_Deglyc (951SI) and FimH_PGDGN_DG-ferritin (995SI) purified from an ExPIGnti expression mammalian system was used to measure their ability to inhibit bacterial binding to SV-HUC cells. A pool of sera raised against AS01 was used as a negative control. [Figure 13] Figure showing the biochemical characterization of purified FimH_PGDGN_DG by SDS-PAGE, SE-UPLC and RP-UPLC. [Figure 14] Figure showing the biochemical characterization of purified FimH_DNKQ_DG by SDS-PAGE, SE-UPLC and RP-UPLC. [Figure 15] Figure showing the biochemical characterization of purified FimH_DNKQ_DG deglycosylation by SDS-PAGE, SE-UPLC and RP-UPLC. [Figure 16-1] Figure showing the biochemical characterization of purified FIMH_DG_PGDGN-ferritin (sequence from UPEC strain 536) containing additional AAs at the N-terminus. [Figure 16-2] Figure showing the biochemical characterization of purified FIMH_DG_PGDGN-ferritin (sequence from UPEC strain 536) containing additional AAs at the N-terminus. [Figure 16-3] Figure showing the biochemical characterization of purified FIMH_DG_PGDGN-ferritin (sequence from UPEC strain 536) containing additional AAs at the N-terminus. [Figure 17]This figure shows FimH-specific total IgG (ELISA). Figure 17A: Anti-FimH IgG titers in mouse serum after dose 3, plotted as a function of MPL dose. Figure 17B: Anti-FimH IgG titers in mouse urine measured after the first, second, and third vaccine doses. Preimmunized serum was used as a negative control. FimHC was immunized in combination with an adjuvant using a protein content of 1.6 μg. [Figure 18A] This figure shows a comparison of bacterial and mammalian expression systems in FimH-specific total IgG (ELISA) serum and urine. (A) Assuming that antibody titers are distributed log-normally, the geometric mean titer (GMT) and its two-sided 95% confidence interval (CI) were calculated. For group comparison, an ANOVA model was fitted to log10 titers with group, time point, and their interactions as fixed factors, and with repeated presentations for time points. Heterogeneity of variance was considered between groups. Geometric mean proportions and their 95% CIs were derived from this model. The antibody response to each formulation was evaluated against FimHDG used for ELISA plate coating. All statistical analyses were performed using SAS 9.4. [Figure 18B] FimH-specific total IgG (ELISA): This figure shows a comparison of bacterial and mammalian expression systems in serum and urine. (B) FimH-specific total urinary IgG. [Figure 19] This figure shows FimH-specific total IgG. ELISA results after dose 1: Assuming that antibody titers are distributed in a log-normal manner, the geometric mean titer (GMT) and its two-sided 95% confidence interval (CI) were calculated. For group comparison, an ANOVA model was fitted to log10 titers with group, time point, and their interactions as fixed factors, and with repeated presentations for time points. Heterogeneity of variance was considered between groups. Geometric mean proportions and their 95% CIs were derived from this model. The antibody response to each formulation was evaluated against FimHDG used for ELISA plate coating. All statistical analyses were performed using SAS 9.4. [Figure 20]This figure shows that FimH-DG induces a functional immune response. The bacterial inhibition assay of the selected construct compared to FimHC. Relative potency is calculated as reported in the examples. [Figure 21] This figure shows the antibody activity of FimHDG antibodies that inhibit ExPEC adhesion using a bacterial inhibition assay (BAI). All candidates were formulated together with AS01. [Figure 22] This figure shows the SPR analysis (sensogram) of the interaction between a FimH sample and mAb926. To study the interaction between FimH candidates and mAb926, SPR analysis was performed to obtain a sensorogram representing the plot of response (vertical coordinate) against time (horizontal coordinate) indicating the progression of the interaction. The response was measured in resonance units (RU), which are directly proportional to the concentration of molecules on the sensor chip surface. Each sensorogram consists of two parts corresponding to the binding and dissociation phases of the interaction. Binding is the first phase in biomolecular interactions, during which the analyte and ligand collide due to diffusion, and binding occurs if the collision is in the correct direction and has sufficient energy. Dissociation is the phase in which the ligand-analyte complex dissociates; the dissociation profile can provide information about the stability of the complex; if the dissociation is slow, the complex stability is higher, and vice versa. [Figure 23A] This figure shows the SDS-PAGE analysis of culture supernatant expressing untagged FimHDG in mammalian cells. SDS-PAGE and SEC-UPLC analysis of purified untagged FimHDG derived from Expi293 cells and ExpiCHO cells. [Figure 23B] This figure shows the nano-DSF profiles and melting temperatures obtained for tagless FimHDG purified from Expi293 and ExpiCHO cells compared with FimHDG containing a C-terminal His tag. [Figure 23C-1] This figure shows the SPR binding analysis of mAb926 and 475 to untagged FimHDG compared to FimHDG His. It also shows the SPR analysis of mannose binding to untagged FimHDG compared to FimHDG His. [Figure 23C-2] This figure shows the SPR binding analysis of mAb926 and 475 to untagged FimHDG compared to FimHDG His. It also shows the SPR analysis of mannose binding to untagged FimHDG compared to FimHDG His. [Figure 23C-3] This figure shows the SPR binding analysis of mAb926 and 475 to untagged FimHDG compared to FimHDG His. It also shows the SPR analysis of mannose binding to untagged FimHDG compared to FimHDG His. [Figure 23D] This figure shows the SDS-PAGE analysis of the supernatant of FimHDG-ferritin constructs containing different linkers and with or without the initial Asp residue. Western blotting analysis of mammalian cell-derived pellets using anti-FimH-specific mouse serum. [Figure 24] This figure shows PROSS-based calculations for introducing stabilizing mutations with increased affinity or stability (bottom left of the graph) into octahedral E. coli nanoparticles (PDB 1EUM) (compared to the other 23 strands). [Figure 25A] This figure shows the SDS-PAGE analysis of total (T) and soluble (S) extracts of WT E. coli ferritin and different mutants. [Figure 25B] This figure shows the SEC profile of mutant 0.5. All constructs have profiles with a strong peak (arrow) during dead volume, which is consistent with nanoparticle formation. [Figure 26] This figure shows NS-EM (negative staining) analysis of E. coli ferritin WT and different mutants (0.5, 2, 2.5, 6). [Figure 27] This figure shows the differential scanning fluorescence (SCFL) analysis of ferritin constructs with thermal profiles. The graph on the left shows the derivative of fluorescence intensity with respect to temperature. The circles in the table on the right indicate mutants with the highest Tm (0.5). [Figure 28]The left-hand figure shows Western blotting analysis of supernatants expressing different nanoparticle constructs of FimH using anti-His antibodies. The asterisk indicates E. coli nanoparticles FimHDG-ferritin (mutant 0.5). On the right, TEM analysis shows the presence of correctly formed ferritin nanoparticles. [Modes for carrying out the invention] [Examples]
[0192] The inventors designed stable (in the absence of FimC) uncomplexed mutants of full-length FimH in which the FimG donor chain peptide [SEQ ID NO: 5] was genetically fused to the C-terminus of FimHp via a 4 or 5-residue linker (DNKQ [SEQ ID NO: 8] or PGDGN [SEQ ID NO: 7]), and obtained a "FimH_DG" protein with the structural and functional properties of FimH in the assembled fimbria. The linker was designed by selecting a highly polar charged residue (DNKQ) or by inserting a proline residue as the first residue of the linker that is expected to support folding in the secondary structure and promote the correct protein structure (PGDGN linker). In addition, FimH L To further reduce its flexibility and mannose binding ability, FimH L A structure in which two glycine molecules are missing from the linker that connects to FimHp (Figure 1A).
[0193] Furthermore, by using nanoparticle design related to FimH, it is possible to expose multiple copies of stabilized FimH and further increase its immunogenicity as a means of realizing a 1-2 dose vaccine.
[0194] Virus-like particles (VLPs) and protein nanoparticles (NPs) are presentation platforms for other antigens with the potential to induce effective B and T cell responses. They possess an intrinsic ability to self-assemble into highly symmetric, stable, and organized structures. Several chimeric VLPs / NPs are being investigated worldwide in preclinical and clinical studies. In particular, the genetic fusion of a ferritin scaffold to viral hemagglutinins resulted in particles that were more immunogenic at one dose in the presence of an adjuvant compared to seasonal influenza vaccines (Nature 2013, 49, 104). The same approach has been used in preclinical studies on numerous other antigens (Chen Y, et al. Vaccine. 2020 Jul 31;38(35):5647-5652). The challenge is not only to genetically engineer correctly assembled particles that present the target antigen, but also to make them manufacturable and scalable. To investigate the potential of self-assembling NPs and VLPs that present FimH candidates, various chimeras have been designed and tested via gene fusion.
[0195] Helicobacter pylori ferritin nanoparticles consist of 24 subunits, allowing trimers of a total of eight desired antigens to be presented within the highly symmetrical octahedral cage structure of the ferritin nanoparticles (Figure 1B). Recently, a 60-mer NP protein i301 nanocage based on Thermotoga maritima 2-keto-3-deoxy-phosphogluconate (KDPG) aldolase has been computer-designed (Hsia Y, et al. Nature. 2016 Jul 7;535(7610):136-9). The stability of i301 has been further improved by mutating two cysteine sites (mI3) (Bruun TUJ, et al. ACS Nano. 2018 Sep 25;12(9):8855-8866) and by fusing a SpyCatcher to the N-terminus of the protein.
[0196] The inventors constructed recombinant plasmids for genetically fusing ferritin, mI3 or encapsulin to the FimH_DG_PGDGN stabilized antigen or the FIMHL and FIMHLCys antigens. To separate the presented antigen from the NP, a linker was added between the two sequences.
[0197] The tested linkers contain repeats of Gly and Ser residues and could also contain an internal 8×His tag to enable protein purification. To increase protein expression and solubility in the E. coli cytoplasm lumen of FimH NP, an FIMHL construct (C24SC65S) with a mutated internal S_S bridge was also fused to ferritin and mI3 and tested for expression and solubility.
[0198] Materials and Methods Cloning and E. coli Expression The FimH-NP bacterial constructs were synthesized as DNA strands by Geneart and directly cloned into pET15-tev, pET21 or pET22 (see Table 1) using the Takara infusion cloning kit. Other constructs were purchased from Geneart as synthetic genes and the target proteins were directly cloned into an expression vector (pTRC-HIS2A from Life Technologies). All synthetic genes were optimized for E. coli expression and included N-terminal, C-terminal or internal HIS tags to enable protein affinity purification. Proteins were expressed in BL21DE3T1r (NEB) or T7shuffle express at 20 °C for 24 h using HTMC medium and IPTG induction.
[0199] After pellet collection, the pellets were resuspended in lysis buffer Cell Lactic Express (Merk) or B-Per solution (Pierce) at 25°C for 1 hour. After centrifugation, visible inclusion bodies (IB) pellets were present and redissolved in urea 8M (U8M). Protein expression and solubility were evaluated by SDS-PAGE of samples collected from the soluble fraction (S) and insoluble fraction (IB).
[0200] Recombinant protein production in mammalian cells The FimH-NP mammalian construct (see Table 2) was synthesized by Geneart as a synthetic gene in pCDNA3.1 or pCDNA3.4 (Life Technologies) vectors. All sequences were codon-optimized for expression in mammalian cells and included an N-terminal leader sequence for secretion into cell culture. This sequence is either the IgK mouse leader sequence METDTLLLWVLLLWVPGSTGD [SEQ ID NO: 9] or the IgK mouse leader sequence followed by 15 additional charged residues AAQPARRARRTKLAL [SEQ ID NO: 78] (Figure 1B).
[0201] To generate recombinant FimH-NP, the expression vector was transfected into Expi293GNTI cells according to the manufacturer's (Life Technologies) instructions. The Expi293F GnTI cell line is derived from genetically modified Expi293F cells and lacks N-acetylglucosaminyltransferase I (GnTI) activity, thus lacking complex N-glycans and resulting in a homogeneously glycosylated recombinant protein.
[0202] In short, 30 μg of pCDNA-FimH-NP expression vector was expressed using ExpiFectamine 293 reagent in a 75 × 10⁶ volts per minute range. 6The cells were transfected into 30 mL cultures containing 1 Expi293F cells. The cells were incubated at 37°C, 120 rpm, and 8% CO2, and after 24 hours, ExpiFectamine 293 transfection enhancers 1 and 2 were added. The cells were further incubated at 37°C for 144 hours. Aliquots of the culture were collected every 24 hours, and NA expression was analyzed by SDS-PAGE and Western blotting (WB). At 72 and 144 hours after transfection, the cell cultures were centrifuged at 1000 rpm for 7 minutes, the supernatant was collected, pooled, clarified by centrifugation, filtered through a 0.22 μm filter, and stored at -20°C until purified.
[0203] PNGase F proteomics grade (P7367, Sigma) was used according to the manufacturer's protocol to examine the glycosylation of mammalian-expressed antigens.
[0204] Western blotting was performed using a standard protocol with anti-his-HRP antibody from Sigma, diluted 1:1000, or anti-FimHL-cys antibody generated in mice using purified bacterial FimHL-cys protein, and a secondary anti-mouse HRP antibody.
[0205] Ni 2+ Affinity chromatography was used to purify NPs from the culture supernatant. The target fractions were pooled and concentrated using a 100 kDa cutoff spin concentrator (Millipore Amicon Ultra); sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to determine protein purity. Recombinant FimH-NPs and FimH-DG antigens were purified by preparative size exclusion chromatography (SEC) equilibrated with PBS buffer.
[0206] All recovered fractions were examined for FimH-NP or FimH-DG protein content by SDS-PAGE. Fractions of interest were pooled, filtered through 22 μm, divided into aliquots, and stored at -20°C.
[0207] Analytical SEC-HPLC and reverse-phase RP-UPLC were performed to evaluate protein size and purity. Furthermore, FimH-NPs were analyzed by dynamic light scattering to further determine molecular weight and nanoparticle assembly, and protein sequence identity was evaluated by LC-MS.
[0208] immunization Twelve female CD1 mice per group were immunized with 15 micrograms of candidate antigens expressed in mammalian or bacterial systems adjuvated with ASO1. All mice received three subcutaneous injections (SC) of 200 μL (PBS dilution) of the antigen mixture or adjuvant alone. Blood was collected via the tail vein at 0 days post-vaccination (pre-immunization), 21 days post-dose I, 35 days post-dose II, and 45 or 49 days post-dose III.
[0209] Analysis of FimH-specific antibodies Serum FimH-specific IgG was measured by enzyme-linked immunosorbent assay (ELISA). Briefly, a 96-well microtiter plate was coated with 100 μL of antigen (1 μg / mL) into each well of a 96-well Nunc Maxsorp plate and incubated overnight at 4°C. 250 μL of (PVP) saturated buffer was added to each well, and the plate was incubated at 37°C for 2 hours. The wells were washed three times with PBT. Next, 100 μL of diluted serum was added to each well, and the plate was incubated at 37°C for 2 hours. The wells were washed three times with PBT. 100 μL of alkaline phosphatase-conjugated secondary antibody serum, diluted 1:2000 in dilution buffer, was added to each well, and the plate was incubated at 37°C for 90 minutes.
[0210] The wells were washed three times with PBT buffer. 100 μL of substrate p-nitrophenyl phosphate was added to each well, and the plate was allowed to rise to room temperature for 30 minutes. 100 μL of 4N NaOH was added to each well, and the OD 405 / 620-630 nm was tracked. Antibody titer was quantified using a multimode microplate reader as a serum dilution giving an absorbance of 0.4 OD.
[0211] BAI assay Bacteria (UTI89 wt_mCherry clone 2) were cultured in a static liquid culture for 3 passages under growth conditions to induce FimH expression. BAI assays were performed using selected conditions: a bacterial density of 0.012 OD / mL and an incubation time of 30 minutes. Bacterial adhesion was measured by microscopic analysis (OPERA Phenix). SV-HUC (ATCC) cells were cultured in SV-HUC complete medium: F12K (Thermo Scientific) supplemented with 10% FBS and antibiotics. Pre-infection medium: complete medium without antibiotics.
[0212] TIFF2023553854000015.tif98160
[0213] SV-HUC cells in a 3×T75 flask (3×10 6 Cells / mL (95% viability) were trypsin-treated (at 37°C for 5 minutes). Cells were seeded in 96-well plates, 3.5 × 10⁶ 4 A 60-well plate containing cells / well (VF = 200 μL / well) was seeded and incubated at 37°C in 5% CO2. Bacterial preparations were prepared during three passages of static liquid culture: UTI89 strain was inoculated from the plate into 20 mL LB (125 mL flask) and incubated overnight under static conditions at 37°C. This dilution / incubation process was repeated three times.
[0214] The culture medium for SV-HUC cells was replaced with antibiotic-free pre-infection medium (200 μL / well).
[0215] A 2× serum solution was prepared in a U-bottom 96-well plate using F12K medium or F12K + 10% FBS as shown below, and further diluted by serial dilution.
[0216] A 1 mL sample of third-passage bacterial culture UTI 89 mcherry clone 2 was transferred to a single test tube and centrifuged at 4500 × g for 5 minutes at room temperature. The bacteria were washed with PBS and pelletized. Finally, the bacterial pellet was resuspended in infection medium at 0.5 OD600 / mL.
[0217] Infection was performed as follows: In each plate, the culture medium was removed, and 50 μL / sample of 2× serum / mannose (20% D-(+)-mannose) solution or infection medium (positive & negative control) was added, followed by 50 μL / sample of 2× inoculum or infection medium (negative control). The plates were incubated for 30 minutes, and 15% to 0.06% serum dilutions were added. The plates were incubated at 37°C in 5% CO2 for 30 minutes, the culture medium was removed, and the plate wells were washed three times with PBS. Bacteria were fixed using 4% formaldehyde (200 μL / well) solution. After incubation for 20 minutes, the fixation solution was removed, and the samples were washed three times with PBS (200 μL / well). DAPI (62248, Thermo Scientific) solution was diluted 1:5000 in PBS, and 100 μL was added to each well. The samples were incubated at room temperature (in the dark) for 10 minutes. The DAPI solution was removed, and PBS was added to each well (200 μL / well). The samples were stored at 4°C in the dark and allowed to RT for 3 hours before imaging with OPERA Phenix. The entire well area was acquired using a 10× air objective lens with Alexafluor488 settings. A Z-stack (4 images) was acquired for each field of view. The data was analyzed using Harmony software. Total bacterial fluorescence area (single object ≤ 100 μm) 2 ) was calculated as the adhesion value.
[0218] result FimH stabilized as a monomeric antigen and FimH-stabilized nanoparticles are secreted as soluble proteins in mammalian expression systems and can be easily purified by IMAC. As an initial attempt, several FimH NP constructs were prepared and tested under various conditions. The solubility of candidate antigens in E. coli was tested using the T7 and pTac promoters of the pET and pTrcHIs2A vectors, respectively. Furthermore, both cytoplasmic and periplasmic expression were tested, and different E. coli strains were optimized for disulfide crosslinking into the cytoplasm as T7 Shuffle expresses. To increase protein expression and solubility of FimH NPs in the E. coli cytoplasm, FimHL constructs with mutated internal S_S crosslinks were also fused to ferritin and mI3 and tested for expression and solubility.
[0219] However, none of the constructs resulted in soluble protein expression, suggesting that the E. coli expression system may not be optimal for obtaining FimH nanoparticles. In the soluble fraction, only faint bands were detected by Western blotting analysis, indicating that mutations in the internal disulfide crosslinks within the FimHL domain did not significantly improve solubility.
[0220] Escherichia coli is a highly favored prokaryotic cell expression system due to its low-cost fermentation and easy process. However, protein production by E. coli can result in recombinant proteins that are insoluble and inactive, and may require complex refolding processes in vitro, often being expressed primarily as inclusion bodies (Figure 2).
[0221] To overcome the insolubility issue in E. coli, the inventors decided to switch to the mammalian EXPI293F expression system. First, the FimH sequence was analyzed for N- and O-glycosylation sites that may be responsible for glycosylation. Figure 3 reports the location of the presumed N-glycosylation site. No O-glycosylation site was detected (data not shown).
[0222] To express bacterial proteins in mammalian cells and minimize glycosylation compared to the E. coli system, the inventors used a genetically mutated EXPI293F cell line (Thermofisher) called Expi293F GnTI. This cell line is derived from genetically modified Expi293F cells but lacks N-acetylglucosaminyltransferase I (GnTI) activity, and therefore lacks complex N-glycans, resulting in homogeneously glycosylated recombinant proteins.
[0223] Full-length FimH protein stabilized by FimG donor chains (FimH-DG) from E. coli strains 536 and / or J96 containing secretory mouse Ig-κ chain leader sequences (+ FimH alone or fused to protein NPs (ferritin, mI3, IMX313, encapsulin, and HBc) LEXPI293 GNTI cells were transfected with the domain (a portion of the construct; Table 1, with additional amino acids at the N-terminus). The accumulation of secreted recombinant proteins was characterized by measuring their expression in the culture supernatant 72 and 144 hours after transfection by WB and SDS-PAGE. Both analyses revealed that FimH soluble expression was obtained at high levels for several constructs, but not for others. Expressed soluble FimH-DG stabilized proteins and FimH-NPs containing a C-terminal 6×His tag or an internal 8×His tag were purified from pooled culture medium at 72 and 144 hours using ionic metal solid-phase chromatography and preparative SEC chromatography. SDS-PAGE analysis of proteins produced in the mammalian expression system revealed that they migrated at high MW compared to the corresponding bacterial proteins, suggesting that they were glycosylated. As a result, two constructs, FimH_DNKQ_DG_deglyc and FimH_PGDGN_DG_deglyc, which lack a putative residue involved in N-glycosylation and contain an additional amino acid at the N-terminus, were mutated to generate the following mutations N28S, N91D, N249D, and N256D (Table 1).
[0224] Western blot analysis of the supernatant of mammalian expression constructs containing additional N-terminal amino acids revealed expression bands corresponding to FimH_DNKQ_DG, FimH_PGDGN_DG, and FimHC complexes. In contrast, FimH_ΔGG_PGDGN_DG (deletion of the glycy residue (reside) linking FimHL and FimHP) was not detected 3 and 6 days after transfection (Figure 4). Protein characterization of the purified product is reported in Figures 13–16.
[0225] The construct FimH_PGDGN_DG_ferritin (536 strain; 995SI), which includes the additional N-terminal amino acid, was successfully expressed and purified. In contrast, all FimH non-FimG donor-chain stabilized constructs, including (936SI)-FimH-IMX313 j96; (935SI)-FimH_mi3 j96; and (929SI)-FimHL-HIS-mI3 j96, which all contain the additional N-terminal amino acid, were not detected in the culture supernatant.
[0226] PNGase treatment of FimH_DG_PGDGN_IMX313 and FimH_DG_PGDGN_ferritin from strain J96 revealed a shift of FimH_DG_PGDGN_IMX313 in the correct MW in the treated samples, suggesting that the protein was glycosylated in mammalian cells. FimH_DG_PGDGN_ferritin from strain J96 was not detected in either the untreated or treated PNGase samples, suggesting that this protein was degraded. FimH_PGDGN_DG_ferritin (strain J96) (1000SI) was not purified from the supernatants recovered from 3 and 6 days, even when the protein was detected immediately after sample recovery, due to degradation, and this construct was not obtained (Figures 5A-5C).
[0227] In addition, the predicted N-glycosylation site reported in Figure 3 was mutated to serine or aspartic acid. The resulting FimH_DNKQ_DGDeglyc candidate showed a higher peptide mapping coverage compared to the WT sequence. This result suggests that possible glycosylation may occur in response to these specific mutated amino acids (Figure 6).
[0228] Furthermore, by removing the additional N-terminal amino acids (short leader), representative constructs reported in Figure 7 were expressed. FimH-DG_PDGDN_ferritin (536 strain, with additional N-terminal AA) was obtained with 88% purity by RP-UPLC. (998SI)FimH_PGDGN_DG-HIS-IMX313 j96 was also well expressed and successfully purified.
[0229] All of these constructs were expressed as soluble proteins secreted in cell culture and further purified as previously described. Western blotting analysis of the supernatant using anti-FimHL-cys antibodies generated with bacterial-stabilized proteins recognized all mammalian-expressed tested NPs (Figure 7).
[0230] To confirm that FimH-Np was correctly assembled, the purified protein was examined by analytical SE-HPLC and DLS analysis. In SE-HPLC, they eluted as a single large, not-sharp peak. Based on a comparison of elution volume (Ev) of ferritin, the NP was run under the same conditions along with molecular weight (MW) standard Ev, and the calculated MW of FimH-DG-PGDGN-ferritin NP is consistent with the NP, which consists of 24 subunits, as confirmed by DLS analysis.
[0231] The construct FimH-DG_PDGDN_ferritinSL (sequence derived from strain 536 or J96, lacking additional N-terminal AA) was highly expressed with the final purity estimated by RP-HPLC.
[0232] The FimHL-NP constructs were also successfully purified, and biochemical characterization confirmed the formation of NPs consisting of 24 subunits for (1095SI)FimHL-HIS-Fer 536 and 60 subunits for (1096SI)FimHL-HIS-Mi3 J96.
[0233] Visualization of generated FIMH-DG NPs Further confirmation that the recombinant FimH-DG_PDGDN_ferritin-additional AA (Figures 9A-9B) fusion proteins FIMH_DG_PGDGN-HIS-ferritin536 short leader and FimH_PGDGN_DG_HIS-ferritin(Ferritn)j96, generated in a mammalian expression system, form stable and correctly assembled NPs was obtained by visualizing the purified proteins using negative-stained electron microscopy (TEM). As shown in Figure 8B, the (995SI)FimH_PGDGN_DG_ferritin536 sample containing the N-terminal additional AA appeared as a homogeneous population of spike-decorated octahedral particles oriented in different directions. Bare ferritin particles exhibited a diameter of 13 nm, while spiked ferritin presented a diameter of 30–32 nm. The diameter difference (8.5 nm) corresponds to the length of FimH (calculated relative to the FimH model). Furthermore, (1142SI)FimH_DG_PGDGN-HIS-ferritin536 was correctly folded and decorated with eight spikes of the FimH trimer. No bare ferritin particles were present in the sample. The particles showed a diameter of 30–32 nm. The (1042SI)FimH_PGDGN_DG_HIS-ferritin (Ferritn)j96 sample presented a mixed population of NPs containing individual or aggregated proteins, with correctly folded spiked NPs displaying eight spikes, accompanied by the presence of folded NPs with multiple spikes and incorrectly folded NPs. No bare ferritin particles were detected (Figure 8D).
[0234] Cryo-EM NS-EM (negative staining) of (1095SI)FimHL-HIS-Fer 536 and (1096SI)FimHL(J96)-mI3-his showed that the NPs expressed in mammalian systems were fully assembled. FimHL-HIS-Mi3 J96(1096SI) presented correctly folded nanoparticles with a highly symmetrical and spike-decorated icosahedral shape of 40 nm, with only slight aggregates (Figures 9A and 9B). In addition, 1185SI and 1184SI FIMH_DG_PGDGN_536-encapsulin, both having a short leader at the N-terminus, were also correctly assembled (Figures 9C and D). The constructs (1043SI)FimH_DG_PGDGN_IMX313_HIS J96 and (998SI)FimH_PGDGN_DG-HIS-IMX313 j96, which contain stabilized FimH fused to IMX313, were also successfully purified, and biochemical characterization confirmed the formation of high molecular weight (HMW) molecular species. However, TEM analysis of these constructs only showed the presence of aggregated proteins (data not shown).
[0235] Structural characteristics of recombinant FimH-DG-ferritin NPs in 3D reconstruction To generate the three-dimensional structure of assembled octahedral particles of (995SI)FimH_PGDGN_DG_ferritin (FimH sequence derived from strain 536), a single-particle reconstruction method was applied to TEM images. FimH-DG_PDGDN_ferritin nanoparticles (box size 64×64 pixels) placed in a single box were first subjected to a bandpass filter to increase the signal-to-noise ratio, followed by alignment by rotation and translation, and finally centering, and then MSA was performed for classification. Figure 10A shows the selection of FimH-DG_PDGDN_ferritin as the most abundant 2D class mean, which is representative of the various orientations of the particles on the carbon film support. The 3D-EM structure of the created soluble FimH-DG_PDGDN_ferritin (Figure 10B) confirmed that this structure consists of a highly symmetrical octahedral cage structure with the presence of three “anchor-like” appendages on three rotation axes.
[0236] FIMH-DG-stabilized protein and FIMH-DG_PGDGN-ferritin NP are highly immunogenic in mice. To evaluate the immunogenicity of candidate proteins expressed in mammalian lines (FimH_PGDGN_DG, FimH_DNKQ_DG, FimH_DNKQ_DGDeglyc, and FimH_PGDGN_DG_ferritin), single serum samples from immunized mice were analyzed by ELISA assay using FimH lectin domains (FimHL) expressed in E. coli as a coating. Overall, all candidates induced an IgG response. FimH_PGDGN_DG and FimH_PGDGN_DG_ferritin showed similar IgG titers; however, the NP candidate showed a more uniform and compact response after dose II. This result suggests that the NP generated an earlier, more effective response compared to the candidates expressed as recombinant proteins. FimH_PGDGN_DG_ferritin immunized at two different doses (15 μg and 3 μg) showed that the lower dose (3 μg) was equivalent to the higher dose (15 μg) in terms of total IgG response, indicating that the ferritin nanoparticles carrying the recombinant FimH_DG_PGDGN protein exhibited good immunogenicity even at the lower tested dose of 3 μg. In addition, the ferritin morphology resulted in a less scattered immune response at the second dose compared to other candidates, including the corresponding FimH construct lacking the nanoparticle domain (Figure 11).
[0237] FimH-DG-stabilized candidate (generated in mammalian systems) exhibits a relatively strong ability to inhibit bacterial adhesion to recombinant (bacterial) forms. The ability of serum generated against FimH-stabilized candidate cells to inhibit bacterial adhesion to human bladder cells was tested using an in vitro bacterial inhibition assay. Antibodies against the vaccine candidates FimH_PGDGN_DG and FimH_PGDGN_DG_ferritin were more effective than FimH_DNKQ_DG or bacterial-generated FimHL-cys candidates in inhibiting bacterial adhesion to urothelial cells. These results indicate that stabilized vaccine candidates based on FimH expressed in mammalian systems have great potential for further vaccine development. Furthermore, the linker used for FimH stabilization played a crucial role in the functionality of the generated antibodies (Figure 12), and constructs with the PGDGN linker were associated with improved results in inhibiting bacterial adhesion.
[0238] conclusion Our research investigated novel FimH candidates stabilized using a donor chain strategy. Vaccine candidates were either produced as single recombinant proteins or assembled into nanoparticles carrying FimH subunits. Since expression in E. coli yielded insoluble products, soluble antigen expression was achieved using a mammalian expression system via transient transfection of EXPI293-GNTI cells. To our knowledge, this expression system has not been previously used to produce bacterial proteins. Because FimH expressed from E. coli was insoluble under all tested conditions, the mammalian expression system improved protein solubility in this case. This expression system enables the production of stabilized FimH_DG antigens in all soluble forms, as well as different FIMH nanoparticles (FimHL-mI3, FimHL-ferritin, and FimHH_DG_PGDGN-ferritin). In contrast, when unstabilized FimH was fused to NPs, no expression was detected, demonstrating that stabilization via the FimG complementary chain is essential for generating full-length isolated FimH protein in mammalian cells and for antigen presentation on ferritin NPs. Deletion of two glycine residues, which are the native linker between FimHL and FimHP, did not result in the expression of FimH_ΔGG_PGDGN_DG containing the additional N-terminal AA, suggesting that this deletion was detrimental to protein stability.
[0239] SDS-PAGE comparison of micromolecules (MWs) of bacterial insoluble proteins and their corresponding mammalian expression proteins showed that they had different molecular weights, suggesting that mammalian proteins are glycosylated, as confirmed by PNGase treatment. All constructs containing the leader sequence (IgK mouse leader sequence alone or with additional amino acids) were successful in the secretion of FimH constructs into expression medium. However, none of the constructs containing additional amino acids produced more uniform nanoparticles (Figures 7 and 9), and no naked ferritin NPs were observed.
[0240] Structural data confirmed that all nanoparticles were correctly assembled and that FimH spikes were detected on the surface of ferritin (24 spikes) and mI3 nanoparticles (60 spikes).
[0241] Our data suggest that the FimH-stabilized candidate expressed in mammalian systems was immunogenic, and that the resulting antibodies were able to inhibit bacterial adhesion to urothelial cells.
[0242] Action of AS01 adjuvant: Improvement of FimHC and FimH-DG To evaluate the contributions of the PHAD and AS01 adjuvant systems to the humoral response, the FimHC protein complex was used as a model antigen and expressed as described in Langermann S, et al. Science. 1997 Apr 25;276(5312):607-11. IgG antibodies generated after vaccination were measured, and relative titers were plotted as a function of the amount of MPL contained in the PHAD and AS01 formulations. Overall, AS01 induced a higher total IgG response than PHAD in mouse serum (after 3 doses) and urine (after 2 and 3 doses). Furthermore, AS01B, used with 5 μg MPL, showed the same IgG levels as PHAD containing 12.5 μg MPL (Figures 17A and 17B).
[0243] Improved antigen design and adjuvant formulations produce a functional immune response after 2 doses (not 3). To evaluate the immune response to the FimHC complex and FimH-stabilized his-tagged forms (FimHDG, i.e., FimH-PGDGN-DG (where DG represents a donor chain complementary peptide derived from FimG), and FimHDG-ferritin, i.e., FimH-PGDGN-DG-linker (containing the His tag)-ferritin (derived from H. pylori)), different antigen doses (0.55 μg or 1.6 μg) adjuvanted with PHAD or AS01 were used for mouse immunization. The FimHC complex was expressed as described in Langermann S, et al. Science. 1997 Apr 25;276(5312):607-11. The protein was expressed in bacteria or mammalian systems. FimH-specific total IgG titers (measured by ELISA) in serum and urine of immunized mice were measured after the second and third vaccine infusions. Serum IgG titers were determined after two and three doses for different formulations of FimHDG prepared with AS01 (Figure 18A). IgG levels were compared to those induced by vaccination with FimHC using the same AS01 adjuvant and PHAD (containing an equivalent amount of MPL as present in AS01). As shown in Figure 18A, at an antigen dose of 0.55 μg, a clear enhancement of the antibody response to FimHC was observed with AS01 compared to PHAD after the second and third doses. Furthermore, a relatively good immune response was observed with FimHDG-His tags expressed and purified from bacterial lines compared to FimHC standards adjuvanted with PHAD.
[0244] Finally, both stabilized FimH candidates purified in mammalian cells (FimHDG-His tagged mammalian and FimHDG-His tagged ferritin) showed a higher response than FimHDG expressed in E. coli. Both mammalian FimHDG constructs at 1.6 and 0.55 μg induced IgG levels, which plateaued after the second and third immunizations. Furthermore, FimHDG at the second dose produced a higher response compared to the three doses of FimHC-PHAD at both tested protein doses (geometric mean ratios of 9.7 and 3, respectively) (Figure 18A). Antibody responses to FimHDG were evaluated in urine collected from immunization groups using relatively high protein doses after the first, second, and third doses. Higher IgG titers were measured in mice vaccinated with the mammalian FimHDG formulation, as observed in the tested serum (Figure 18B).
[0245] For the selected immunization group, the total IgG response after dose 1 was also determined. After dose 1, FimHDG-ferritin nanoparticles induced a GMT twice as high as ferritin-free FimHDG (at any Ag dose), but the variability was higher than that after doses 2 and 3 (resulting in a large 95% CI including 1).
[0246] Compared to bacterial antigens, the mammalian form adjuvanted with ASO1 induced a relatively high IgG response after doses I and II (observed GMRs ranged from 7.1 to 60.8, with all lower limits of 95% CI greater than 1), but the response was similar after the third dose (observed GMR around 1.5 times) (Figure 19).
[0247] Comparison of different linkers (mammals / bacteria) in relation to relative efficacy To investigate the effects of different linkers, FimHDG expressed in both bacterial and mammalian systems was compared to FimHC for bacterial inhibition (BAI) of adhesion to urothelial cells. Figure 20 shows that all FimHDG constructs were more functional than FimHC, independently of the expression system (bacterial or mammalian) used for expression. Interestingly, FimHDG constructs possessing the PGDGN linker were more effective than the DNKQ construct. These data suggest that linkers can stabilize FimH in different conformations, resulting in different functional antibody responses. The BAI assay has been conceived as a multi-dilution assay, where the sample to be tested is plated at different concentrations along with a reference pool of serum to estimate the dose-response curve. The signal is standardized between 0% and 100% before titer calculation. The titer is expressed as the relative potency (RP) of the test sample relative to the reference pool by comparing it to the corresponding dose-response curve. In detail, the RP is calculated by considering dilution on a logarithmic scale and fitting a four-parameter logistic (4PL) constrained model (as described in Chapter 5.3 of the European Pharmacopoeia), where the upper and lower asymptotes, which are the standard and test sample gradient factors, are constrained to be equal. The RP is calculated using the EC between the reference and the sample. 50 It is calculated as the ratio between EC. 50 The θ is calculated from the 4PL constraint inflection point and inversely transformed (antilog). The model requires that the reference and sample curves have the same slope factor (parallelism) and the same maximum and minimum response levels at the extreme points (linearity). The suitability of the parallelism and linearity assumptions is evaluated for each session by determining the p-value for testing deviations from parallelism, the p-value for testing deviations from linearity, and the slope ratio between the reference and sample.
[0248] FimH-DG induces a functional immune response in relation to BAI, HAI, and conformational mAb binding. Furthermore, the antibody activity of anti-FimHDG antibodies that inhibit ExPEC adhesion was evaluated using a bacterial inhibition assay (BAI). Data on antibody activity revealed that serum induced against both bacterial and mammalian FimHDG constructs showed higher bacterial adhesion inhibition ability than FimHC standard serum. Among the candidates tested, FimHDG-ferritin showed at least 10-fold higher activity compared to similar FimHDG constructs (Figure 21). Similar results were obtained using a HAI assay.
[0249] The FimHC complex was expressed as described in Langermann S, et al. Science. 1997 Apr 25;276(5312):607-11. "FimHDG" means FimH-PGDGN-DG, where DG represents a donor chain complementary peptide derived from FimG, and "FimHDG-ferritin" means FimH-PGDGN-DG-linker (including His tag)-ferritin (derived from H. pylori). BAI assays and relative potency calculations were performed as described in the previous examples.
[0250] FimHDG and mAb962 coupling SPR analysis was performed to study the interaction between FimHDG (i.e., FimH-PGDGN-DG, where DG represents the donor chain complementing peptide derived from FimG) and mAb926 (Dagmara I. Kisiela et al (2015)). Monomeric forms of FimHDG obtained from bacterial or mammalian lines (i.e., FimH-PGDGN-DG, where DG represents the donor chain complementing peptide derived from FimG) showed similar binding affinity to mAbs, with some differences in binding and dissociation profiles. FimHDG-ferritin (FimH-PGDGN-DG-linker (including His tag)-ferritin (derived from H. pylori)) resulted in a more stable interaction compared to the monomer form, likely due to multimerization with increased avidity. In contrast, the lower interaction of mAb926 with FimHC compared to FimHDG suggested that FimHDG was stabilized in its pre-binding conformation as expected. Indeed, mAb926 was generated against the FimH-stabilizing lectin domain with significantly reduced mannose-binding ability (pre-binding conformation) (Dagmara I. Kisiela et al., (2013)), while FimC stabilized FimH in its elongated post-binding-like form (Sauer et al., (2016), Nature Communications volume 7, Article number: 10738) (Figure 22). The FimHC complex was expressed as described in Langermann S, et al. Science. 1997 Apr 25;276(5312):607-11.
[0251] Evaluation of the new linker Recombinant protein synthesis in mammalian cells Novel constructs were designed by inserting different linkers between the FimH_DG gene and the nanoparticle (NP) monomer to generate FimHDG (i.e., FimH-PGDGN-DG, where DG represents a donor chain complementary peptide derived from FimG) and FimHDG nanoparticles, which do not contain internal or C-terminal repeating His residues. The FimH-NP mammalian construct was synthesized by Geneart or Twist as a synthetic gene in a pCDNA3.4 (Life Technologies) vector. All sequences were codon-optimized for expression in mammalian cells and included an N-terminal leader sequence for secretion into cell culture. This sequence is either the IgK mouse leader sequence METDTLLLWVLLLWVPGSTG, or the IgK mouse leader sequence followed by the aspartate residue METDTLLLWVLLLWVPGSTGD to evaluate the contribution of this residue to effective protein secretion. To generate recombinant FimH-NP, the expression vector was transfected into Expi293 cells and / or ExpiCHO cells according to the manufacturer's instructions (Life Technologies), and the culture supernatant was collected 5 days after transfection. Protein purification was achieved by ion-exchange chromatography followed by a preparative SEC purification step.
[0252] Nano-DSF analysis NanoDSF analysis was performed to evaluate fluorescence monitoring unfolding of FimHDG constructs. Samples were manually loaded into nanoDSF-grade standard capillaries in triple repeats and transferred to a Prometheus NT.48 nanoDSF device. An excitation wavelength of 280 nm was used for endogenous tryptophan fluorescence measurements, and tryptophan fluorescence emission was measured at 330 nm, 350 nm, and their ratio (350 nm / 330 nm). Data were analyzed using Prometheus PR. Control software (NanoTemper Technologies) and plotted using fluorescence ratio against temperature.
[0253] SPR analysis The FimHDG construct was diluted with running buffer HBS-EP+ (0.01M HEPES, 0.15M NaCl, 0.003M EDTA, and 0.05% v / v surfactant P20), and Ni 2+ The ions were pre-activated by injecting a 0.5 mM solution and then captured on the surface of a sensor chip NTA that had been washed with 3 mM EDTA. The mAbs were captured at a concentration of 20 μg / mL on the surface of a CM5 sensor coated with secondary anti-mouse IgG Fc. Each sample at a fixed concentration of 50 nM was injected onto the surface of the sensor chip over a period of 180 seconds. Dissociation was tracked over a period of 600 seconds. Finally, the sensor chip was regenerated using 10 mM glycine-HCl pH 1.7. The experiment was performed using a Biacore T200 instrument (GE Healthcare) and analyzed using Biacore T200 evaluation software 3.0 (GE Healthcare).
[0254] result: Full-length FimH-DG-stabilized untagged protein containing a secretory mouse Ig-κ chain leader sequence, both alone and fused to protein NP (ferritin), was used to transfect EXPI293 and ExpiCHO cells. The accumulation of secreted recombinant protein was characterized by measuring its expression in the culture supernatant 5 days after transfection using SDS-PAGE. Analysis revealed that soluble FimHDG expression was obtained at high levels for the untagged construct in both Expi293 and ExpiCHO cells (Figure A). The protein was further purified from the culture supernatant and biochemically characterized compared to previously purified His-tagged FimHDG and bacterial refolded FimHDG. Untagged FimHDG was obtained from both EXpi293 and ExpiCHO cells with good purity levels on SDS-PAGE and SE-UPLC. Compared to bacterial cells, proteins in mammalian cells move with a higher molecular weight (around 42 kDa) on SDS-PAGE than their theoretical value (31 kDa) due to glycosylation (Figure 23A).
[0255] The folding of untagged purified FimDG was analyzed by nanoDSF, and the melting temperature was obtained and compared with that obtained for FimHDG-HIS. FimH-DG showed good thermal stability in nanoDSF with two temperature transitions compared to the lectin (Tm1) and pyrin (Tm2) domains, while the His-tagged FimHDF molecule showed only one transition, likely due to a different folding. Furthermore, the untagged protein showed higher stability of the pyrin domain transition (higher melting temperature value) compared to the His-tagged molecule (Figure 23B). This different folding in the His-tagged construct compared to untagged FimHDG is likely due to the absence of both the N-terminal aspartate residue and the C-terminal His tag.
[0256] SPR analysis of mammalian-generated FimHDG untagged constructs (Figure 23C) shows that mAb926 can bind to the construct with differences in its binding profile compared to the his-tagged FimHDG protein. Furthermore, the untagged FimHDG protein exhibits weak interactions with mAb VH_475 and mannose, unlike the his-tagged FimHDG, which is consistent with the different folding observed with respect to the untagged construct compared to the his-tagged protein.
[0257] To generate untagged FimHDG-ferritin NPs, the His tag was replaced with a different linker to separate the FimHDG molecule from the nanoparticle monomer sequence. The designed and tested linkers were made from flexible residues such as glycine and serine, thereby allowing the linked protein domains to move freely relative to each other. The inventors tested linkers of different lengths and found that relatively longer linkers could ensure that two adjacent domains did not sterically interfere with each other, but may be more susceptible to degradation. The linker AKFVAAWTLKAAA, also known as the pan-HLA DR-binding epitope (PADRE), is antigen-specific CD4 +This peptide activates T cells and has been proposed as a suitable carrier epitope for use in the development of synthetic and recombinant vaccines. The linkers GGGGSLVPRGSGGGGS and EAAAKEAAAKEAAAKA are rigid linkers. Linker AEAAAKEAAAKEAAAKA, stabilized by Glu-Lys salt crosslinking, forms an α-helix structure (Marqusee & Baldwin, 1987). Since untagged FimHDG and His-tagged FimHDG also differ in their initial aspartic acid residue, some of the linkers were tested both in the absence and presence of the N-terminal aspartic acid residue. Plasmids encoding different constructs were used for Expi293 transfection. Five days after transfection, only the constructs beginning with the N-terminal aspartic acid residue (D) (untagged or his-tagged) showed a band of secreted protein in the supernatant visible by SDS-PAGE (Figure 23D). The constructs FimHDG_HIS_ferritin 1619SI and 1042SI have the same sequence except for the first aspartic acid residue, but only construct 1042SI was secreted and present in the culture supernatant of EXPI, confirming the importance of this residue at the N-terminus of FimHDG for achieving efficient secretion of FimHDG-ferritin nanoparticles. Among the different linkers tested, only the constructs FimHDG-ferritin untagged 1623SI and 1627SI from E. coli strains J96 and 536, which have the first aspartic acid residue, resulted in secretion. Western blotting analysis was also performed to evaluate the expression of untagged FimHDG-ferritin 1433SI in the absence of the first Asp residue, and it was confirmed that the protein was expressed in the pellet fraction and not only present in the culture supernatant.
[0258] Stability study of E. coli ferritin in silico material and method Evolutionary constraints on the design of Escherichia coli ferritin based on sequence and structure. The goal of this study was to design symmetric systems such as self-assembling protein nanoparticles. This approach introduced stabilizing mutations using a combination of computational physics-based algorithms and evolutionary bioinformatics. To achieve this objective, consensus sequence design was performed on asymmetric units or monomers of E. coli ferritin using the Rosetta suite (Alford RF, et al. J Chem Theory Comput. 2017 Jun 13;13(6):3031-3048) for thermodynamic design and a non-redundant evolutionary homolog (PSI-BLAST, Altschul SF, et al. Nucleic Acids Res. 1997 Sep 1;25(17):3389-402) to limit the mutation space (PDB:1EUM WorldWideWeb(www).rcsb.org / structure / 1EUM). To optimize the energy theory of protein subunits at geometric interfaces, the designed model was constrained within a symmetric framework (DiMaio F, et al PLoS One. 2011;6(6):e20450). This symmetry-based pipeline was then implemented in a modified version of the structural bioinformatics tool PROSS (Goldenzweig A, et al. Mol Cell. 2016 Jul 21;63(2):337-346) to obtain a list of in silico-stabilized sequences (SEQ ID NOs. 149-152 and Figure 24).
[0259] Protein expression and purification Genes encoding various mutants of E. coli-stabilized ferritin and wild-type ferritin were cloned into the pET15TEV vector. These genes included an N-terminal 6×His tag and a TEV cleavage site. Plasmids encoding various constructs were transformed into E. coli BL21DE3t1r competent cells. For protein expression, cells were grown at 20°C in HTMC ON and induced with 1 mM IPTG at 20°C for 24 hours. CeLytic TMSoluble proteins were extracted by chemical dissolution using Express (Sigma Aldrich), purified using a nickel chelate column, and then subjected to preparative size exclusion chromatography using a Superdex 200® Increase 10 / 300 GL column (Cytiva). Purity was confirmed by SDS-PAGE (Figure 25).
[0260] Transmission electron microscopy (TEM) analysis For negative staining, 5 μL of sample (diluted to 20 ng / microliter) was loaded onto a 300 square meter glow-discharge copper mesh grid for 30 seconds. After removing excess, the grid was negatively stained with Nano-W stain (Ted Pella) for 30 seconds. The samples were analyzed using a Tecnai G2 spirit, and images were acquired using a Veleta CCD (Figure 26).
[0261] Thermo Fluorescence The ThermoFluor assay is a rapid temperature-based assay for evaluating protein stability. In this method, each sample is diluted to a final concentration of 0.2 mg / mL with an additional 4 μL of SYPRO Orange dye 1000× (Molecular Probes), and then diluted to a final volume of 40 μL using buffer solution. This mix is pipetted into the wells of a 96-well thin-walled PCR plate (Bio-Rad), and water is added to the control sample. Each sample was analyzed in triple replicates. The melting point (T) of each protein was determined by increasing the temperature from 25°C to 100°C using a scan rate increment of 1°C per minute, while performing fluorescence measurements at each 1°C step. m The unfolding profile and melting temperature were monitored using a quantitative PCR thermal cycler (Stratagene). All DSF experiments were performed in triple replicates. The derivative of fluorescence intensity was plotted as a function of temperature, and the reported T m This is the inflection point of the S-curve determined using GraphPad Prism software (Figure 27).
[0262] result Recombinant generation of in silico-stabilized E. coli ferritin nanoparticles To obtain stabilized nanoparticles derived from E. coli that present a stabilized E. coli-specific antigen (FimHDG, i.e., FimH-PGDGN-DG, where DG represents a donor chain complementary peptide derived from FimG), an innate ferritin scaffold for repeated presentation of FimH was selected and optimized on a computer. The Rosetta-based design approach maintained octahedral symmetry and focused on the interface between the monomer and 23 other chains in the symmetric system (Figure 24). This strategy, which possesses stabilized ferritin derived from E. coli that presents the E. coli-specific antigen (FimH), is a rational approach to maintaining species or genus-specific design by using an innate scaffold for repeated presentation of the antigen.
[0263] Four of the representative mutants (SEQ ID NOs. 149-152) of all in silico-stabilized sequences created by E. coli WT ferritin and PROSS were highly expressed and soluble when produced as recombinant His-tagged proteins in E. coli cell lines (Figure 25). The constructs were successfully purified using affinity purification steps followed by preparative size exclusion chromatography. Peaks corresponding to high molecular weight fractions were recovered for all constructs and further analyzed using electron microscopy to assess the proper formation of homogeneous and well-structured nanoparticles. TEM analysis showed that all samples, with the exception of mutant 2.5 which had heterogeneous morphology, produced correctly folded ferritin nanoparticles (Figure 26).
[0264] To identify the most stable E. coli ferritin nanoparticles, the thermal stability of recombinant ferritin constructs (WT, 0.5, 2, 6) was evaluated by differential scanning fluorescence (DSF) using Sypro Orange, which binds to hydrophobic residues and detects their exposure during protein unfolding. The ferritin protein exhibited very high thermal stability, as expected with respect to the protein nanocage, with the initial unfolding transition detected around 74°C–76°C. This DSF analysis demonstrated that the E. coli mutant (0.5) protein showed the highest shift in thermal unfolding, which led to the selection of this mutant as the preferred construct to be fused with the FimHDG antigen, based on this increase in stability.
[0265] Mammalian generation of E. coli-stabilized ferritin that presents the FimHDG antigen. To test whether stabilized and innate ferritin nanoparticles could be used as scaffolds for the presentation of the FimHDG antigen (i.e., FimH-PGDGN-DG, where DG represents a donor chain complementary peptide derived from FimG), the FimHDG sequence (including the secretory sequence Igk) was genetically fused to the gene of stabilized ferritin (mutant 0.5) as a substitute for H. pylori ferritin. To enable affinity purification of the recombinant secretory nanoparticles in mammalian cell culture supernatant, the two molecules were separated by a linker containing a repeating histidine sequence. This construct was used for transfection of Expi293 Gnti cells, and the accumulation of the secreted recombinant protein was characterized by evaluating its expression in the culture supernatant 5 days after transfection using Western blotting analysis with an anti-His antibody. Analysis revealed that FimHDG-ferritin (mutant 0.5) nanoparticles were successfully secreted into the cell supernatant. Purified FimHDG-ferritin (mutant 0.5) nanoparticles were visualized by transmission electron microscopy, confirming the correct morphology of ferritin-stabilized nanoparticles and the surface presentation of the FimHDG antigen with a size of approximately 20 nm (Figure 28).
[0266] This data demonstrates that stabilized E. coli ferritin nanoparticles presenting FimHDG can be successfully generated in mammalian cells, indicating that it is possible to design nanoparticles using both naturally occurring antigens and scaffolds for target pathogens.
[0267] [Table 1A] TIFF2023553854000017.tif247170TIFF2023553854000018.tif113170
[0268] [Table 1B] TIFF2023553854000020.tif109170
[0269] [Table 2] TIFF2023553854000022.tif241170TIFF2023553854000023.tif235170TIFF20235538540 00024.tif241170TIFF2023553854000025.tif243170TIFF2023553854000026.tif243170 TIFF2023553854000027.tif237170TIFF2023553854000028.tif237170TIFF20235538540 00029.tif242170TIFF2023553854000030.tif242170TIFF2023553854000031.tif242170
[0270] [Table 3] TIFF2023553854000033.tif235170TIFF2023553854000034.tif230170TIFF2023553854000035.tif240170TIFF2023553854000036.tif240170TIFF2023553854000037.tif240170TIFF2023553854000038.tif230170TIFF2023553854000039.tif236170TIFF2023553854000040.tif241170TIFF2023553854000041.tif241170TIFF2023553854000042.tif241170TIFF2023553854000043.tif239170TIFF2023553854000044.tif238170TIFF2023553854000045.tif243170TIFF2023553854000046.tif243170TIFF2023553854000047.tif243170TIFF2023553854000048.tif238170TIFF2023553854000049.tif244170TIFF2023553854000050.tif196170
Claims
1. A polypeptide comprising or consisting of the amino acid sequence X-(a)-L-(b)-Y, wherein "(a)" is a FimH polypeptide; or a variant, fragment and / or fusion of FimH; "L" is an optional first linker; "(b)" is a donor strand complementary amino acid sequence, "X" is an optional N-terminal amino acid sequence; "Y" is an optional C-terminal amino acid sequence, and "Y" is not derived from FimC or FimH or a fragment thereof.
2. 2. The polypeptide of claim 1, wherein one or more amino acids known or predicted to be N-glycosylated or O-glycosylated are substituted with serine (S), alanine (A), aspartic acid (D), or glutamine (Q).
3. 3. The polypeptide of claim 2, wherein (a) comprises one or more of the following amino acid substitutions compared to SEQ ID NO:2: N28S, N91D, N249D, N256D, or at positions of SEQ ID NO:101, 103 and 105 corresponding to those positions in SEQ ID NO:2, e.g., one, two, three or four of said amino acid substitutions.
4. (b) is: (i) 6 to 28 amino acids of SEQ ID NO: 3; or a fragment and / or variant thereof; or (ii) 8 to 36 amino acids of SEQ ID NO: 4; or a fragment and / or variant thereof. A polypeptide according to any one of claims 1 to 3, comprising or consisting of:
5. (b) is: (A) the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6; (B) an amino acid sequence comprising 1 to 10 single amino acid changes, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 single amino acid changes, compared to SEQ ID NO:5 or SEQ ID NO:6; (C) a fragment of at least 7 consecutive amino acids from SEQ ID NO:5, e.g., at least 8, 9, 10, 11, 12, or 13 consecutive amino acids from SEQ ID NO:5, or (D) a fragment of at least 7 consecutive amino acids from SEQ ID NO:6, e.g., at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 consecutive amino acids from SEQ ID NO:
6. A polypeptide according to any one of claims 1 to 4, comprising or consisting of:
6. 6. The polypeptide according to any one of claims 1 to 5, wherein (b) comprises or consists of an amino acid sequence according to SEQ ID NO:
5.
7. (b) is: (i) linked directly to the C-terminus of (a); or (ii) linked to the C-terminus of (a) via a first linker; A polypeptide according to any one of claims 1 to 6.
8. (ii) The polypeptide of any one of claims 1 to 7, wherein the first linker or "L" comprises or consists of 2 to 20 amino acids, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids.
9. The polypeptide according to any one of claims 1 to 8, wherein the first linker begins with a proline.
10. 10. The polypeptide of any one of claims 1 to 9, wherein the first linker comprises or consists of polar amino acids, e.g., the first linker is entirely composed of polar amino acids, or, if the first linker begins with a proline, the remaining amino acids are polar.
11. The first linker comprises: (i) PGDGN [SEQ ID NO: 7], or a variant or fusion thereof; or (ii) DNKQ [SEQ ID NO: 8], or a variant or fusion thereof 11. The polypeptide according to any one of claims 1 to 10, comprising or consisting of:
12. 12. The polypeptide of any one of claims 1 to 11, comprising a nanoparticle domain at the N-terminus or C-terminus, and optionally wherein "X" or "Y" comprises a nanoparticle domain.
13. The nanoparticle domain comprises: (i) ferritin (e.g., [SEQ ID NO: 15] or [SEQ ID NO: 109] (Helicobacter pylori), [SEQ ID NO: 16] (Escherichia coli), or any one of [SEQ ID NO: 149] to [SEQ ID NO: 152] (stabilized E. coli)), or a mutant and / or fragment thereof; (ii) iMX313 (e.g., [SEQ ID NO: 17]), or a variant and / or fragment thereof; (iii) mI3 (e.g., SEQ ID NO: 18), or a variant and / or fragment thereof; (iv) encapsulin (e.g., [SEQ ID NO: 19]), or a variant and / or fragment thereof; or (v) a self-assembling viral envelope protein, such as Acinetobacter phage AP205 envelope protein (NCBI Reference Sequence: NP_085472.1), Hepatitis B virus core protein (HBc) [SEQ ID NO: 110], or bacteriophage Qβ [SEQ ID NO: 111], or a variant and / or fragment thereof.
13. The polypeptide of claim 12, selected from the group consisting of:
14. The nanoparticle domain comprises: (i) directly linked to the polypeptide; or (ii) linked to the polypeptide via a second linker; 14. A polypeptide according to claim 12 or 13.
15. The nanoparticle domain comprises: (i) upstream of (a); (ii) the N-terminus of the polypeptide; (iii) downstream of (b); or (iv) the C-terminus of the polypeptide The polypeptide according to any one of claims 12 to 14,
16. (i) having at least 80% sequence identity, e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, to the amino acid sequence SEQ ID NO:16, and having one or more mutations selected from the group consisting of a glycine (G) at a position aligned to residue 34 of SEQ ID NO:16 (T34G mutation), an aspartic acid (D) at a position aligned to residue 70 of SEQ ID NO:16 (N70D mutation), an isoleucine (I) at a position aligned to residue 72 of SEQ ID NO:16 (V72I mutation), and an alanine (A) at a position aligned to residue 124 of SEQ ID NO:16 (S124A mutation); (ii) having at least 80% sequence identity, e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence SEQ ID NO:16, and including at least one of a glycine (G) at a position aligned to residue 34 of SEQ ID NO:16 (T34G mutation), an aspartic acid (D) at a position aligned to residue 70 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 72 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 73 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 74 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 75 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 76 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 77 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 78 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 79 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 80 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 82 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a position aligned to residue 83 of SEQ ID NO:16 (N70D mutation), an aspartic acid (D) at a and an isoleucine (I) at a position aligning to residue 124 of SEQ ID NO:16 (V72I mutation) and an alanine (A) at a position aligning to residue 124 of SEQ ID NO:16 (S124A mutation), and optionally the polypeptide monomer comprises an amino acid sequence having at least 80% sequence identity, e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence SEQ ID NO:149; (iii) having at least 80% sequence identity, e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, to the amino acid sequence SEQ ID NO:16, and having a glycine (G) at a position aligned to residue 34 of SEQ ID NO:16 (T34G mutation), an isoleucine (I) at a position aligned to residue 72 of SEQ ID NO:16 (V72I mutation), and an alanine (A) at a position aligned to residue 124 of SEQ ID NO:16 (S124A mutation), optionally wherein the polypeptide monomer comprises an amino acid sequence having at least 80% sequence identity, e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, to the amino acid sequence SEQ ID NO:150; (iv) an amino acid sequence having at least 80% sequence identity, e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, to the amino acid sequence SEQ ID NO:16, and having a glycine (G) at a position aligning to residue 34 of SEQ ID NO:16 (T34G mutation) and an alanine (A) at a position aligning to residue 124 of SEQ ID NO:16 (S124A mutation), optionally wherein the polypeptide monomer comprises an amino acid sequence having at least 80% sequence identity, e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, to the amino acid sequence SEQ ID NO:151; (v) A polypeptide monomer comprising or consisting of an amino acid sequence having at least 80% sequence identity, e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, to the amino acid sequence SEQ ID NO:16 and having a glycine (G) at a position aligning to residue 34 of SEQ ID NO:16 (T34G mutation), optionally wherein the polypeptide monomer comprises an amino acid sequence having at least 80% sequence identity, e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, to the amino acid sequence SEQ ID NO:
152.
17. 17. The polypeptide monomer of claim 16, comprising an amino acid sequence selected from the group consisting of SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, and SEQ ID NO:
152.
18. 18. A nanoparticle comprising a polypeptide monomer according to claim 16 or 17.
19. 20. The nanoparticle of claim 18, wherein the nanoparticle is a homo-oligomer.
20. 20. The nanoparticle of claim 18 or 19, wherein the outer or inner surface structure of the nanoparticle carries one or more antigens and / or immunostimulants.
21. The nanoparticle of claim 20, wherein the antigen comprises or consists of a polypeptide according to any one of claims 1 to 15.
22. 22. The nanoparticle of claim 21, comprising or consisting of an amino acid sequence having at least 80% sequence identity, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, to the amino acid sequence of SEQ ID NO: 130 or 153.
23. 23. The polypeptide according to any one of claims 1 to 22, comprising or consisting of an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 123 or SEQ ID NO: 124, such as 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 123 or SEQ ID NO:
124.
24. A polypeptide according to any one of claims 1 to 23, wherein the mannose binding of the polypeptide is at least 20% lower than that of native FimH complexed with native FimC (FimHC complex), for example at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% lower.
25. 25. The polypeptide of any one of claims 1 to 24, wherein FimH is in a low affinity conformation, i.e., in a tense (T) state.
26. 26. The polypeptide of any one of claims 1 to 25, wherein the autoaggregation induced by the polypeptide is at least 20% lower than that of native FimH, such as at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% lower.
27. 27. The polypeptide of any one of claims 1 to 26, which is capable of inhibiting bacterial adhesion by at least 20%, such as at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%.
28. A polypeptide described in any one of claims 1 to 27, wherein the anti-FimH immunogenicity of the polypeptide is at least 20% higher, for example at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400% or 500% higher, than that of native FimH complexed with native FimC (including in particular FimH in the high-affinity conformation, relaxed (R) state (see above)).
29. 29. The polypeptide of any one of claims 1 to 28, which is capable of inhibiting hemagglutination of guinea pig red blood cells by at least 2 fold, such as at least 3 fold, 4 fold, 5 fold, 10 fold, 15 fold, 20 fold, 25 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, or 100 fold.
30. A nucleic acid encoding a polypeptide according to any one of claims 1 to 29, for example a DNA or RNA encoded by any one of SEQ ID NOs: 45 to 77, 90 to 99, or a variant and / or fragment thereof.
31. 31. The nucleic acid of claim 30, which is codon-optimized for expression in a selected prokaryotic or eukaryotic cell, such as a yeast cell (e.g., Saccharomyces cerevisiae, Pichia pastoris), an insect cell (e.g., Fall armyworm Sf21 cell, or Sf9 cell), or a mammalian cell (Expi293, Expi293GNTI, Chinese hamster ovary (CHO) cell, and human embryonic kidney 293 cell (HEK293)).
32. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 29 or a nucleic acid according to claim 30.
33. A vaccine comprising a polypeptide according to any one of claims 1 to 29 or a nucleic acid according to claim 30 or 31.
34. 34. The vaccine of claim 33, further comprising an adjuvant.
35. 35. The vaccine of claim 34, wherein the adjuvant comprises any one of 3D-MPL, QS21 and a liposome, such as a liposome comprising cholesterol.
36. 36. The vaccine of claim 35, wherein the adjuvant comprises a liposome comprising 3D-MPL, QS21 and cholesterol.
37. 37. The vaccine of any one of claims 33 to 36, which generates a protective immune response after 1 or 2 doses.
38. Use of a polypeptide according to any one of claims 1 to 29, a nucleic acid according to claim 30 or 31, or a vaccine according to any one of claims 33 to 37 for the manufacture of a medicament for raising an immune response in a mammal, such as for the treatment and / or prevention of one or more diseases.
